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Abstract
Induction of drug-metabolizing enzymes through the antioxidant response element (ARE)-
dependent transcription was initially implicated in chemoprevention against cancer by 
antioxidants. Recent progress in understanding the biology and mechanism of induction revealed a 
critical role of induction in cellular defense against electrophilic and oxidative stress. Induction is 
mediated through a novel signaling pathway via two regulatory proteins, the nuclear factor 
erythroid 2-related factor 2 (Nrf2) and the Kelch-like erythroid cell-derived protein with CNC 
homology-associated protein 1 (Keap1). Nrf2 binds to Keap1 at a two site-binding interface and is 
ubiquitinated by the Keap1/cullin 3/ring box protein-1-ubiquitin ligase, resulting in a rapid 
turnover of Nrf2 protein. Electrophiles and oxidants modify critical cysteine thiols of Keap1 and 
Nrf2 to inhibit Nrf2 ubiquitination, leading to Nrf2 activation and induction. Induction increases 
stress resistance critical for cell survival, because knockout of Nrf2 in mice increased 
susceptibility to a variety of toxicity and disease processes. Collateral to diverse functions of Nrf2, 
genome-wide search has led to the identification of a plethora of ARE-dependent genes regulated 
by Nrf2 in an inducer-, tissue-, and disease-dependent manner to control drug metabolism, 
antioxidant defense, stress response, proteasomal degradation, and cell proliferation. The 
protective nature of Nrf2 could also be hijacked in a number of pathological conditions by means 
of somatic mutation, epigenetic alteration, and accumulation of disruptor proteins, promoting drug 
resistance in cancer and pathologic liver features in autophagy deficiency. The repertoire of ARE 
inducers has expanded enormously; the therapeutic potential of the inducers has been examined 
beyond cancer prevention. Developing potent and specific ARE inducers and Nrf2 inhibitors holds 
certain new promise for the prevention and therapy against cancer, chronic disease, and toxicity.
I. Introduction
Electrophiles and oxidants are ubiquitous to aerobic organisms arising from both xenobiotic 
challenge and internal metabolism (Raymond and Segrè, 2006; Halliwell and Gutteridge, 
2007; Ma, 2010). Although some electrophiles and oxidants have physiological functions 
participating in enzymatic reactions, cell signaling, and defense against microbes, many are 
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capable of causing harm to the cell as a result of their reactive chemistry. Electrophiles, such 
as benzo-[a]pyrene arene oxide, could form DNA adducts through their electron-deficient 
centers to cause mutations. Oxidants, such as reactive oxygen species (ROS1), could damage 
macromolecules to cause lipid peroxidation, protein amino acid side-chain oxidation, and 
DNA single- and double-strand breaks. A growing body of evidence indicates that oxidants 
and electrophiles are among the principal agents responsible for the development of toxicity 
and diseases, such as cancer, chronic inflammatory disease, arthrosclerosis, 
neurodegeneration, and aging (Bossy-Wetzel et al., 2004; Finkel, 2005; Storz, 2005). On the 
other hand, most species have evolved with elaborate intrinsic strategies to cope with 
electrophilic and oxidative insults (Talalay et al., 1988; Kensler et al., 2007; Ma, 2010).
Drug-metabolizing enzymes (DMEs) metabolize and detoxify electrophiles and oxidants 
(Talalay et al., 2003; Ma and Lu, 2012). Cytochrome P450s catalyze the mono-oxygenation 
of chemicals, which often serves as the first step of metabolism. A group of heterogeneous 
enzymes carry out the “phase II reactions” that include 1) a nucleophilic trapping reaction 
between an electrophilic substrate and GSH through glutathione transferase (GST), 2) a 
nucleophilic reaction between an epoxide and water via epoxide hydrolase, 3) a conjugation 
reaction by UDP-glucuronosyl-transferase (UGT) and sulfotransferase that converts 
lipophilic chemicals to water-soluble glucuronide and sulfate conjugates to facilitate 
excretion through the bile and urine, and 4) a reduction reaction, such as the obligatory two-
electron reduction of quinones and quinonoids by NAD(P)H:quinone oxidoreductase 1 
(NQO1). Chemicals and their metabolites are transported out of cells through drug 
transporters for distribution and elimination. The antioxidant systems—including superoxide 
dismutase, catalase, glutathione peroxidase, peroxiredoxin, and thioredoxin—detoxify ROS 
directly.
Many DMEs are induced transcriptionally. Induction is controlled by a group of xenobiotic-
activated receptors (XARs), transcription factors that are evolved from several phylogenetic 
families to mediate the adaptive response to chemical exposure (Ma, 2008). XARs include 
the basic helix-loop-helix--PER/ARNT/SIM (periodicity/aryl hydrocarbon receptor nuclear 
translocator/simple-minded) protein aryl hydrocarbon receptor (AhR) and the zinc finger 
nuclear receptors pregnane X receptor and constitutive androstane receptor. XARs control 
the induction of DMEs in response to elevated concentrations of specific chemicals to 
increase the rate of turnover of the chemicals. Induction subsides as the inducers are 
metabolized. In this manner, chemical sensing is directly coupled with transcription of the 
1Abbreviations: βNF, β-naphthoflavone; a.a., amino acid(s); AhR, aryl hydrocarbon receptor; AP-1, activator protein 1; ARE, 
antioxidant response element; ATF, activating transcription factor; Bach, BTB and CNC homolog; BBN, N-nitrosobutyl(4-
hydroxybutyl)amine; BHA, butylated hydroxyanisole; BHT, butylated hydroxytoluene; bp, base pair(s); Bp, benzo[a]pyrene; BTB, 
Bric-a-brac, tramtrack, broad-complex; bZip, basic region leucine zipper; CBP, cAMP response element-binding protein-binding 
protein; CDDO, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid; CNC, cap ‘n’ collar; CTR, C-terminal region; Cul3, cullin 3; 
DC, DGR plus CTR; DGR, double glycine repeat; DME, drug-metabolizing enzyme; DRE, dioxin response element; ECH, erythroid 
cell-derived protein with CNC homology; ERα, estrogen receptor α; FEV1, forced expiratory volume in 1 s; GSK, glycogen synthase 
kinase; GST, glutathione transferase; HO-1, heme oxygenase 1; iNOS, inducible nitric-oxide synthase; IVR, intervening region; 
Keap1, Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1; Maf, musculoaponeurotic fibrosarcoma 
protein; MARE, Maf recognition element; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NF-κB, nuclear factor-κB; NFE2, 
nuclear factor erythroid 2; NQO1, NAD(P)H:quinone oxidoreductase 1; Nrf2, nuclear factor erythroid 2-related factor 2; PKC, protein 
kinase C; RAR, retinoic acid receptor; Rbx1, RING box protein 1; ROS, reactive oxygen species; SCF, Skp1-Cul1-F-box; SNP, 
single-nucleotide polymorphism; tBHQ, tert-butyl hydroquinone; TPA, 12-O-tetradecanoylphorbol 13-acetate; TRE, TPA response 
element; UVR, UV radiation; VCD, 4-vinylcyclohexene diepoxide; XAR, xenobiotic-activated receptor.
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enzymes through an XAR, enabling the body to respond to a xenobiotic challenge quickly 
and as needed. Early studies revealed that planar aromatic hydrocarbons, such as 
benzo[a]pyrene (Bp), induce both CYP1A1 and the “phase 2” enzymes GST, NQO1, and 
UDP glucuronosyltransferase and are called bifunctional inducers, whereas, some other 
inducers, such as the antioxidant tert-butyl hydroquinone (tBHQ), induce “phase 2” 
enzymes only and are named monofunctional inducers (Talalay et al., 1978; Prochaska and 
Talalay, 1988). Induction by bifunctional inducers is mediated through AhR and requires the 
dioxin response element (DRE) located in the enhancers of the enzymes’ genes (Whitlock, 
1999). Induction by monofunctional inducers, however, requires a XAR and DNA 
regulatory sequence distinct from AhR and DRE (Prochaska and Talalay, 1988; Rushmore 
and Pickett, 1990).
The DNA regulatory sequence responsible for induction by monofunctional inducers was 
identified as an antioxidant response element (ARE) (Rushmore and Pickett, 1990; Favreau 
and Pickett, 1991), also called the electrophile response element (Friling et al., 1990). ARE 
contains a consensus sequence 5′-TGACnnnGC-3′ and was found in the regulatory regions 
of rat and mouse Gst and Nqo1 genes. The XAR for induction by monofunctional inducers 
was identified in late 1990s from an unexpected source. The nuclear factor erythroid 2-
related factor 2 (Nrf2) is a transcription factor similar in structure and DNA-binding activity 
to the nuclear factor erythroid 2 (NFE2), a transcription factor key to the regulation of β-
globin expression during erythropoiesis and platelet development (Moi et al., 1994). Unlike 
NFE2, Nrf2 is expressed broadly and does not seem to be critical for hematopoiesis; instead, 
it was found to mediate the induction of ARE-dependent DMEs by monofunctional inducers 
(Venugopal and Jaiswal, 1996; Itoh et al., 1997).
The identification of Nrf2 as the XAR for induction of ARE-dependent DMEs spurred an 
array of subsequent studies that not only revealed the signaling pathway of induction but 
also provided significant insights into the molecular mechanism by which cells defend 
against electrophiles and oxidants. For example, molecular and structural analyses of the 
degradation of Nrf2 in un-stimulated cells and the activation of Nrf2 by monofunctional 
inducers shed light into the mechanisms that underlie the specificity, efficacy, and plasticity 
of chemical sensing and signal transduction toward oxidants and electrophiles by Nrf2. 
Targeted knockout of Nrf2 and Keap1 (Kelch-like erythroid cell-derived protein with CNC 
homology-associated protein 1) in mice helped to reveal the involvement of the Nrf2-ARE 
pathway in the development of a variety of diseases and toxicity. Identification of a plethora 
of ARE-regulated genes at a genomic scale provided a rationale for the diverse functions of 
Nrf2. Last, but not least, developing new and potent ARE inducers led to new approaches 
for disease prevention and therapy. In retrospect, the past 15 years have witnessed a rapid 
advancement in the study of ARE-dependent gene regulation that has significantly 
influenced our understanding of the molecular basis of oxidative and electrophilic defense.
In this review, we discuss major issues with regard to transcriptional regulation of ARE-
dependent genes through the Nrf2-ARE pathway, the function of Nrf2 in mammalian 
resistance to oxidants and electrophiles, and the preventive and therapeutic potentials of 
Nrf2 in the battle against cancer, chronic disease, and toxicity. The possibility that persistent 
activation of Nrf2 causes more harm than benefit under certain conditions is also discussed. 
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Nrf2 target genes expand rapidly beyond DMEs, but all use ARE as a common regulatory 
element. In the following sections, we designate the genes induced by monofunctional 
inducers through Nrf2 as “ARE-dependent genes” and monofunctional inducers as “ARE-
dependent inducers.”
II. The Nuclear Factor Erythroid 2-Related Factor 2–Antioxidant Response 
Element (Nrf2-ARE) Pathway: Finding the Xenobiotic-Activated Receptor
A. Antioxidant Response Element-Dependent Inducers
The interest in ARE-dependent inducers originated from the observation that phenolic 
antioxidants, such as butylated hydroxyanisole (BHA), a once widely used food additive in 
the United States, protected animals from the carcinogenic and toxic effects of polycyclic 
aromatic hydrocarbons, such as Bp, which led to the concept of “chemoprevention” 
(Wattenberg, 1972, 1985). Subsequently, BHA supplemented in rodent diet was found to 
inhibit the formation of mutagenic metabolites of Bp, and inhibition was associated with 
induction of GSTs and NQO1 (but not CYP1A1), paving the road for mechanistic study of 
chemoprevention (Benson et al., 1978; Pearson et al., 1983).
ARE inducers consist of several types of chemicals, including 1) redox-active bisphenols, 
quinones, and phenylenediamines; 2) Michael acceptors; 3) isothiocyanates; 4) 
thiocarbamates; 5) dithiolethiones; 6) dimercaptans; 7) hydroperoxides; 8) metals and 
derivatives; 9) polyphenols; 10) triterpenoids; 11) polyenes; 12) particles and fibers; and 13) 
protein factors (Fig. 1). The inducers differ considerably in structure but share certain 
chemical properties. Many inducers are electrophiles or redox-active compounds capable of 
modifying protein cysteine thiols by oxidation, reduction, alkylation, and metal chelation. 
This finding suggests that modification of protein cysteine thiols is a key mechanism of 
chemical sensing for ARE inducers (Talalay et al., 1988; Dinkova-Kostova et al., 2001).
Some inducers, such as Michael reaction acceptors and metals, induce ARE-dependent 
DMEs by binding to the cysteine thiols of Keap1 and Nrf2. Polyphenols and triterpenoids—
two large groups of inducers with complex structures—are listed as distinct groups even 
though they contain diphenol or Michael acceptor structures. Some inducers, such as BHA 
and β-naphthoflavone (βNF), acquire thiol-reactive properties after oxidative metabolism. 
BHA is converted to tBHQ through dealkylation to induce ARE-dependent genes. βNF, a 
bifunctional inducer, is oxidized to a redox-active quinone intermediate; therefore, βNF 
induces GSTA1 and NQO1 through a dual signaling mechanism: 1) direct binding to AhR to 
activate DRE-dependent transcription and 2) activating the Nrf2-ARE pathway through its 
quinone metabolites (Rushmore and Pickett, 1990). Fibers and particles may promote ARE-
dependent gene expression via surface-bound chemicals that undergo redox cycling to 
generate ROS; alternatively, fibers and particles stimulate cells to produce endogenous 
inducing agents. Some proteins, such as autophagy substrate p62 and p53-regulated protein 
p21, are called “disruptor” proteins because they activate Nrf2 to induce ARE-dependent 
genes by disrupting Nrf2-Keap1 binding, comprising a novel group of endogenous inducers 
(Chen et al., 2009b; Komatsu et al., 2010).
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ARE inducers are derived from a variety of sources (Fig. 2). A large number of 
phytochemicals and derivatives are capable of inducing ARE-dependent genes and are 
chemopreventive. Oleanolic acid is a natural triterpenoid and is used in Chinese herbal 
medicine for treatment of liver disease. Synthetic triterpenoids, some of which contain the 
CDDO [2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid] structure, are among the most 
potent inducers of ARE-dependent genes examined to date (Dinkova-Kostova et al., 2005, 
2010). Oltipraz, a substituted 1,2-dithiole-3-thione originally developed as an 
antischistosomal drug, induces GSTs and NQO1 and was identified as an effective 
chemopreventive agent in humans (Kensler et al., 2000). Induction of ARE-dependent genes 
by auranofin—a gold-containing antirheumatoid arthritis drug—is thought to help reduce 
drug toxicity in target joints (Kataoka et al., 2001). Many environmental chemicals and 
substances induce ARE-dependent genes as an adaptive response to toxic stimuli.
A growing list of endogenous inducers has been identified. The cyclopentenone 
prostaglandins 15-deoxy-Δ12,14-prostaglandin J2 and prostaglandin A2 activate Nrf2 to 
induce heme oxygenase 1 (HO-1) and peroxiredoxin 1, which contribute to the anti-
inflammatory activity of Nrf2 (Itoh et al., 2004). Nitro-fatty acids are electrophilic signaling 
mediators formed in vivo via nitric oxide (NO)- and nitrite-dependent reactions, some of 
which are structurally similar to 15-deoxy-Δ12,14-prostaglandin J2 and activate Nrf2 by 
modifying Keap1 cysteine codes (Kansanen et al., 2011; Tsujita et al., 2011). 4-
Hydroxynonenal, acrolein, and nitric oxide modify the alkenal and NO sensors of Keap1 
(McMahon et al., 2010). As discussed, p62 and p21 induce ARE-dependent genes by 
interfering Nrf2-Keap1 binding. Although endogenous inducers are not as potent as 
synthetic triterpenoids for induction, their presence in target tissues at critical time points 
makes them important regulators of ARE-dependent genes in physiology and disease. To 
date, many ARE inducers have been examined for preventive and therapeutic applications in 
animals and some in humans.
B. Antioxidant Response Element and Antioxidant Response Element-Dependent Genes
1. Antioxidant Response Element—The 5′ regulatory sequence of the rat Gsta2 gene 
contains a 41-base pair enhancer sequence that was responsive to βNF in the presence of 
AhR but was different from DRE (Telakowski-Hopkins et al., 1988; Rushmore et al., 1990). 
The enhancer also mediated induction of the gene by tBHQ and redox-active diphenols 
independently of AhR, from which the name antioxidant response element was derived 
(Rushmore and Pickett, 1990; Rushmore et al., 1991). An identical sequence was found in 
the enhancer of the mouse Gsta1 gene for induction by tBHQ, dimethyl fumerate, and 
trans-4-phenyl-buten-2-one and was named the electrophile response element (Friling et al., 
1990). Similar ARE sequences were found in rat and human NQO1 genes (Favreau and 
Pickett, 1991; Jaiswal, 1991) and several other DMEs and transporters (Ma, 2012). ARE 
was also required for the basal expression of these genes.
Deletion and mutation analyses of the 41-bp ARE of rat Gsta2 identified a core sequence, 5′-
TGACnnnGC-3′, that is essential for induction by ARE inducers (Rushmore et al., 1991). 
The core sequence was extended into a 20-bp and later a 16-bp consensus sequence through 
comparison among AREs from rat, mouse, and human GST and NQO1 genes and mutation 
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studies. The 16-bp consensus is expressed as 5′-TMAnnRTGAYnnnGCR-3′, where M = A 
or C, R = A or G, Y = C or T, W = A or T, and n = any base (Wasserman and Fahl, 1997; 
Nioi et al., 2003). The 5′-TMA (i.e., T-A/C-A) bases of the consensus seem to be necessary 
for induction of some ARE-dependent genes in addition to the core.
The 5′-TGAC-3′ tetranucleotide within the ARE core is similar to the half-site of the TPA 
(12-O-tetradecanoylphorbol 13-acetate) response element (TRE), 5′-TGAGTCA-3′. AP-1 
proteins bind to TRE in response to phorbol esters, growth factors, and a variety of stress 
signals—such as UV light, metals, and oxidative stress—to induce “immediate response” 
genes. Although AP-1 proteins are capable of binding ARE in vitro with a low affinity, 
several lines of evidence distinguished ARE-dependent transcription from TRE-dependent 
transcription. First, the 3′-GC box of the ARE core sequence was critical for ARE 
inducibility and could separate the ARE core from TRE for induction by tBHQ or TPA 
(Nguyen et al., 1994). Second, many ARE inducers failed to activate TRE transcription but 
induced ARE transcription in cells that lacked endogenous TRE-binding proteins (Prestera 
and Talalay, 1995). Third, although tBHQ induced protein binding at both ARE and TRE, 
the major ARE-binding protein(s) activated by tBHQ was not AP-1; on the other hand, 
tBHQ induced c-Jun, junB, fra-1, and fra-2, which form Fra-containing inhibitory AP-1 
complexes to antagonize the transcriptional effects of TPA at TRE by Jun-Fos heterodimer 
(Yoshioka et al., 1995).
ARE resembles the NFE2-binding motif, 5′-TGCTGAGTCAC-3′, found in the DNase 1 
hypersensitive site 2 of the β-globin locus control region (Moi and Kan, 1990) and the 
enhancer of the porphobilinogen deaminase gene (Mignotte et al., 1989). NFE2 forms a 
heterodimer with a small Maf (musculoaponeurotic fibrosarcoma) protein to bind the 
sequence and control the transcription of the genes during hematopoiesis (Andrews et al., 
1993a,b; Igarashi et al., 1994). The NFE2-binding motif contains TRE and can be bound by 
several transcription factors, including Nrf2. Nrf2 is not a natural binding protein of the 
NFE2-binding motif; however, as discussed below, the similarity between ARE and the 
NFE2-binding motif provided the initial clue that led to the identification of Nrf2 as a bona 
fide mediator of ARE transcription.
The core region of ARE also resembles the Maf recognition element (MARE). The 
palindromic MARE is either 5′-TGCTGAG/CTCAGCA-3′ (13 bp), which has a TRE in the 
core, or TGCTGAGC/CGTCAGCA (14 bp), which contains a cAMP response element in the 
core (Kataoka et al., 1994; Kerppola and Curran, 1994). MARE is recognized by a Maf 
homodimer that binds to the GC dinucleotide of MARE. Nrf2 forms a heterodimer with a 
small Maf to bind ARE, where Nrf2 recognizes the ARE core and the small Maf binds to the 
3′-end GC dinucleotide of ARE (Kurokawa et al., 2009).
These findings suggest that the basic leucine zipper (bZip) proteins—such as NFE2, Nrf1, 
Nrf2, Nrf3, Bach1 (BTB and CNC homolog 1), Bach 2, small Mafs, AP-1 proteins, and 
cAMP-response element binding protein/ATF—exhibit both unique and overlapping 
specificities in DNA recognition and transcriptional regulation by means of dimerization and 
overlapping DNA recognition, which, in the case of Nrf2, expands its capacity to regulate 
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the cellular defense against electrophilic and oxidative stress under physiological and 
disease conditions.
2. Antioxidant Response Element Dependent Genes—In recent years, genome-
wide search for ARE-dependent genes has expanded the repertoire of ARE-dependent genes 
far beyond the originally studied DMEs (Kwak et al., 2003; Lee et al., 2003; Rangasamy et 
al., 2004; Shen et al., 2005; Hayes et al., 2010; Malhotra et al., 2010; He and Ma, 2012). 
ARE-dependent genes are involved in a variety of cellular functions. For example, Nrf2 
controls the transcription of an array of DMEs and transporters, including oxidation 
enzymes (CYP2A5 and ALDH3A1), reduction enzymes (NQO1 and AKR1B3), conjugation 
enzymes (UGT1A1 and SULT3A1), enzymes catalyzing nucleophilic trapping reactions 
(GSTs, mEH, and ES-10), and multidrug resistance-associated proteins 2 and 3. By 
controlling the basal and inducible expression of DMEs and transporters, Nrf2 regulates the 
metabolic fate of numerous exogenous and endogenous chemicals. An emerging function of 
ARE-dependent genes is associated with antioxidant defense and oxidant signaling. In this 
context, Nrf2 regulates the cellular oxidant level and function by 1) increasing catabolism of 
oxidants (superoxide dismutase, peroxiredoxin, and glutathione peroxidase); 2) regeneration 
of oxidized redox factors (thioredoxin and GSSG); 3) synthesis of antioxidants and reducing 
equivalents (GSH and NADPH); 4) suppression of antioxidant inhibitors (thioredoxin-
interacting protein); 5) induction of redox transporter proteins (xCT), metal-binding proteins 
(metallothioneins), and oxidative stress response proteins (HO-1); and 6) expression of 
signaling molecules for ROS-stimulated programs (p62 for autophagy deficiency and 
nuclear respiratory factor-1 for mitochondrial biogenesis) (Ma, 2013). Nrf2 also controls the 
expression of clusters of genes involved in proteasomal protein degradation, cell 
proliferation, and stress responses.
A combined analysis of Nrf2 chromatin immunoprecipitation sequencing profiling, basal 
target gene microarray [Nrf2(−/−) versus wild type], and inducible target gene microarray 
[Keap1(−/−) versus wild type] provided certain insights into direct and indirect gene 
regulation by Nrf2 (i.e., genes regulated by Nrf2 through binding to ARE versus genes 
regulated by Nrf2 but with no apparent Nrf2 binding) (Malhotra et al., 2010). A basal gene 
expression cluster for “cell proliferation” regulation was segregated from an inducible 
cluster for “stress response” in the analysis.
Transcriptional regulation of ARE-dependent genes through the ARE pathway has been 
experimentally demonstrated for some, but not all, of the genes. The identified ARE 
sequences exhibit certain heterogeneity: some have embedded “TRE” motif; some bear the 
5′-TCA motif; some have the ARE core only; and some exist in more than one copy in a 
target gene. This heterogeneity of ARE sequences contributes to the functional diversity of 
the Nrf2-ARE pathway in the regulation of the basal and inducible expression of ARE-
dependent genes. In addition, Nrf2 cross-interacts with several other signaling pathways—
such as NF-κB, AhR, p53, and homeodomain transcription factors—which also expands the 
scope of Nrf2-regulated genes (Ma et al., 2004; Iida et al., 2007; Shin et al., 2007; Li et al., 
2008; Pitha-Rowe et al., 2009; Malhotra et al., 2010).
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The question in searching for the XAR that controls induction of ARE-dependent genes is 2-
fold: 1) what transcription factor (or factors) bind ARE and mediate transcription and 2) 
what protein (or proteins) control the activation of the transcription factor by ARE inducers?
1. The Antioxidant Response Element-Binding Proteins, Nuclear Factor 
Erythroid 2-Related Factor 2 and Small Musculoaponeurotic Fibrosarcoma 
Proteins—Nrf2 was first cloned through expression cloning using a tandem NFE2-binding 
motif as a screening probe (Moi et al., 1994). On the basis of structure, Nrf2 belongs to the 
cap ‘n’ collar (CNC) bZip family of transcription factors, which includes NFE2 (Andrews et 
al., 1993a; Chan et al., 1993b), Nrf1 (Chan et al., 1993a), Nrf2, Nrf3 (Kobayashi et al., 
1999), Bach1 (Oyake et al., 1996), and Bach2 (Muto et al., 1998). NFE2, the founding 
member of the group, controls the developmental expression of hematopoietic genes, such 
as β globin and porphobilinogen deaminase. Disruption of NFE2 resulted in a severe defect 
in platelet formation (Shivdasani and Orkin, 1995). Nrf1 was identified by virtue of its 
binding to NFE2-binding motif and is expressed broadly in mammalian tissues. Knockout of 
Nrf1 is lethal to embryos in mice as a result of anemia and severe liver damage at 
midgestation (Chan et al., 1998). Like Nrf1, Nrf2 is expressed in a broad range of tissues, 
but disruption of Nrf2 in mice did not cause severe phenotypes in the early life of the mice; 
therefore, Nrf2 was initially thought to be dispensable for mouse development (Chan et al., 
1996).
The close resemblance between NFE2-binding motif and human NQO1 ARE, in 
conjunction with a similar tissue expression pattern among Nrf1, Nrf2, and NQO1, raised 
the possibility that the Nrf proteins modulate ARE-mediated induction of human NQO1. 
Indeed, overexpression of Nrf1 or Nrf2 significantly increased induction of ARE-driven 
reporter expression by βNF and tBHQ (Venugopal and Jaiswal, 1996). This notion was 
examined genetically in a separate study (Itoh et al., 1997). Compared with wild type, the 
basal expression and induction of GSTs and NQO1 by phenolic antioxidants in the liver and 
intestine of Nrf2-null mice was largely eliminated, and Nrf2 was shown to heterodimerize 
with a small Maf protein to bind to ARE. These and subsequent studies from several 
laboratories provided evidence to establish Nrf2 as the bona fide transcription factor that 
mediates ARE-driven basal expression and induction of ARE-dependent genes.
The human Nrf2 protein consists of 605 or 589 amino acids, and mouse Nrf2 protein 
consists of 597 or 581 amino acids, depending on the starting codon used (Moi et al., 1994) 
(Fig. 3). Nrf2 protein has a predicted molecular mass of ~66 kDa but shows an apparent 
molecular mass of ~96 kDa on SDS-polyacrylamide gel electrophoresis, possibly because of 
the abundance of acidic amino acid residues and/or post-transcriptional modifications. Nrf2 
contains a bZip motif in the C-terminal half; the basic region is responsible for DNA 
recognition, whereas the leucine zipper mediates dimerization with a small Maf protein. 
Juxtaposed at the N terminus of bZip is a region of approximately 36 amino acids (termed 
CNC because of its homology with CNC, a Drosophila melanogaster segmentation protein) 
and other CNC bZip proteins (Mohler et al., 1991; Moi et al., 1994). Comparison between 
human and chicken Nrf2 amino acid sequences led to the identification of six highly 
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conserved domains designated Neh (Nrf2-ECH homology) domains 1 through 6 (ECH = 
erythroid cell-derived protein with CNC homology = chicken Nrf2) (Itoh et al., 1995). CNC 
bZip is within Neh1. Located within the N-terminal half are Neh4 and Neh5, which confer 
transactivation activities individually and synergistically; transactivation involves 
cooperative binding of the domains with coactivator CBP (Katoh et al., 2001). Neh3 at the C 
terminus of Nrf2 also assists transactivation through interaction with chromatin remodeling 
protein CHD6 (Nioi et al., 2005). Neh6 is localized between Neh5 and Neh1 and may 
function as a degron to mediate degradation of Nrf2 in the nucleus (McMahon et al., 2004). 
Neh2 at the N terminus was particularly noted because it is highly conserved across species, 
and deletion of Neh2 resulted in a marked increase in Nrf2 transactivation activity; 
moreover, negative regulation by Neh2 could be antagonized by coexpression of a Neh2-
GBD fusion protein, suggesting that Neh2 negatively regulates Nrf2 by binding to a 
repressor protein (Itoh et al., 1999). A bipartite nuclear localization signal was identified 
between residues 494 and 511 and mediates nuclear import of Nrf2, whereas a nuclear 
export signal was found between residues 545 and 554 for nuclear export of the protein (Jain 
et al., 2005).
The Maf proteins consist of large Mafs (v-Maf, c-Maf, MafA, MafB, and NRL) and small 
Mafs (MafF, MafG, MafK, and MafT) (Motohashi et al., 1997; Yang and Cvekl, 2007). The 
founding member of the group, v-Maf, is an oncogene encoding the transforming 
component of the avian musculoaponeurotic fibrosarcoma virus AS42 (Nishizawa et al., 
1989). Maf proteins contain a bZip domain for DNA binding and dimerization (Fig. 3). 
Large Mafs have a distinctive acidic transactivation domain in the N-terminal region, 
whereas small Mafs (~18 kDa) lack such a transactivation domain. Small Mafs mainly form 
heterodimers with CNC bZip transcription factors in which the CNC bZip protein binds to 
the core sequence of a DNA response element, such as ARE, and provides the 
transcriptional activation function, whereas the small Maf binds to the GC dinucleotide of 
the elements contributing to high affinity and specific DNA-binding (Kurokawa et al., 
2009).
2. The Cytoplasmic Repressor Kelch-Like Erythroid Cell-Derived Protein with 
CNC Homology-Associated Protein 1 (Keap1)—The modular and titratable 
inhibitory activity of Nrf2 Neh2 domain led to a search for the repressor protein(s) that 
inhibit(s) Nrf2 through Neh2. From a yeast two-hybrid screening using Neh2 as a bait, a 
novel cytoplasmic protein was identified and was named Keap1 for Kelch-like erythroid 
cell-derived protein with CNC homology-associated protein 1 (Itoh et al., 1999), because of 
its homology with D. melanogaster actin-binding protein Kelch (Xue and Cooley, 1993). 
Several lines of evidence support that Keap1 is a bona fide regulator of Nrf2 and a sensor of 
ARE inducers. Keap1 has a broad expression pattern similar to that of Nrf2, binds to Neh2 
both in vitro and in vivo, and suppresses Nrf2 transactivation activity in a number of assays. 
Suppression of Nrf2 by Keap1 is liberated by electrophilic agents. Knockout or knockdown 
of Keap1 results in constitutive activation of Nrf2 (Itoh et al., 1999; Wakabayashi et al., 
2003). Molecular elucidation of Keap1-Nrf2 interaction uncovered a novel mechanism of 
chemical sensing and signaling for induction of ARE-dependent genes by electrophiles and 
oxidants.
Ma and He Page 9













Both human and mouse Keap1 proteins are polypeptides of 624 amino acid residues with a 
predicted molecular mass of ~68 kDa (Fig. 3). Keap1 has two readily recognizable canonical 
protein-protein interacting motifs: a BTB (Bric-a-brac, tramtrack, broad-complex) domain 
[amino acid (a.a.) residues 61–179] and a DGR (double glycine repeat) domain (a.a. 315–
598) (also called Kelch domain because of its six Kelch repeats) (Itoh et al., 1999). In 
addition, Keap1 contains an N-terminal region (a.a. 1–60) domain at the N terminus, an IVR 
(intervening region) domain (a.a. 180–314) between BTB and DGR (also called linker 
region), and a CTR (C-terminal region) domain (a.a. 599–624) at the C terminus. The BTB 
domain and the N-terminal portion of IVR mediate homodimerization of Keap1 as well as 
binding with Cul3. The DGR and CTR together form a six-bladed propeller structure and are 
therefore defined jointly as the DC domain that mediates the interaction with Nrf2 Neh2 
(Tong et al., 2006). It is noteworthy that Keap1 is rich in cysteine residues, with 25 cysteines 
in mouse and rat and 27 in human Keap1 proteins. Some cysteine residues are located 
adjacent to basic residues and have properties of reactive cysteines that have low pKa values 
and are excellent targets of electrophiles and oxidants.
3. Other Proteins—Although Nrf1 was found capable of stimulating ARE-driven gene 
transcription when overexpressed in cells, direct evidence of its role in ARE-driven gene 
induction is lacking. Nonetheless, Nrf1 and Nrf2 have overlapping functions during early 
development, because a double knockout of Nrf1 and Nrf2 in mice caused early embryonic 
lethality and excessive oxidative stress that were distinct from the midgestation lethality 
found in homozygous Nrf1 knockout and no apparent embryonic death in homozygous Nrf2 
knockout mice (Leung et al., 2003).
The Bach proteins are more distantly related among CNC bZip proteins. Bach proteins often 
act as transcription repressors (Toki et al., 2005; Igarashi and Sun, 2006). Bach1 
heterodimerizes with MafK, and Bach1/MafK dimer binds to the E1 and E2 enhancers of 
human heme oxygenase 1 gene promoter (located at around −4.0 and −9.0 kb) to repress 
HO-1 expression. Each enhancer contains multiple copies of AREs (also called StRE or 
MARE by different laboratories). Heme induces HO-1 by releasing Bach1 from the 
enhancers, whereas ARE inducers induce the gene by stimulating Nrf2 binding to the AREs 
(Alam et al., 1995, 2000; Sun et al., 2002; Dohi et al., 2006; He et al., 2007; Reichard et al., 
2007). In a manner similar to that of HO-1, Bach1/small Maf competes with Nrf2/small Maf 
to suppress ARE-driven NQO1 basal expression and induction by tBHQ, whereas heme 
relieves the inhibitory effect of Bach1 to stimulate NQO1 expression (Dhakshinamoorthy et 
al., 2005).
Although Nrf2-null mice showed substantial reduction in the basal expression and induction 
of Nqo1 and Gsts (class Alpha and Mu subunits), some Gsts—such as Gsta1 and/or Gsta2, 
Gsta4, and Gstm1—were still induced in the intestine by BHA, coumarin, and diterpenes 
(Itoh et al., 1997; McMahon et al., 2001; Higgins et al., 2008). This variability in Nrf2-
dependence of intestinal ARE-dependent genes for induction suggests that additional factors 
other than Nrf2 are activated by ARE inducers to mediate induction of the genes in the 
tissue in the absence of Nrf2. Given the heterogeneity of ARE sequences and overlapping 
DNA-binding activities among bZip proteins, it is possible that Nrf1, AP-1, or other bZip 
transcription factors mediate the induction of some ARE-dependent genes in the intestinal 
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epithelium of Nrf2 knockout mice. It is equally possible that adaptive changes in Nrf2-null 
cells, such as increased oxidative stress, synergize with ARE inducers to activate an 
alternative inducing mechanism(s) that is not functional in the presence of Nrf2 otherwise.
III. Mechanism of Nuclear Factor Erythroid 2-Related Factor 2 Regulation: 
Insights from Structure
A key question raised after Nrf2 and Keap1 were identified was how Nrf2 is regulated for 
induction of ARE-dependent genes.
A. Nuclear Factor Erythroid 2-Related Factor 2 Turnover through the Ubiquitin-26S 
Proteasome Pathway
Nrf2 mRNA is readily detectable in a wide range of cells, implying that transcription of 
Nrf2 is not a major mechanism by which Nrf2 is regulated. A clue of post-transcriptional 
regulation of Nrf2 was provided when induction of NQO1 was compared with induction of 
CYP1A1 in the presence of cycloheximide, a potent inhibitor of protein synthesis. Induction 
of CYP1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin (a potent AhR ligand) was markedly 
enhanced by cycloheximide, a phenomenon termed “superinduction.” Superinduction of 
CYP1A1 results from inhibition of synthesis of a labile inhibitory protein (called AhR 
degradation-promoting factor), which promotes proteasomal degradation of ligand-activated 
AhR (Ma and Baldwin, 2000; Ma et al., 2000). In contrast, the basal expression and 
induction of NQO1 by tBHQ or 2,3,7,8-tetrachlorodibenzo-p-dioxin were totally blocked by 
cotreatment with cycloheximide, suggesting that a labile protein was required for the basal 
expression and induction of NQO1 by either inducer (Ma and Kinneer De-Fede, 2001). The 
labile factor was subsequently found to be Nrf2, which is degraded through the 
ubiquitin-26S proteasome pathway with a half-life of 20 min (Sekhar et al., 2002; McMahon 
et al., 2003; Kobayashi et al., 2004; Ma et al., 2004; He et al., 2006). The findings also 
indicate that the AhR-DRE pathway cross-interacts with the Nrf2-ARE pathway for 
induction NQO1 by bifunctional inducers (Ma and Kinneer De-Fede, 2001; Ma et al., 2004).
A number of molecular, biochemical, and genetic studies implicated Keap1 in the control of 
the ubiquitination-proteasomal degradation of Nrf2. In this framework, Keap1 controls the 
ubiquitination of Nrf2 by acting as an adaptor protein to bring Nrf2 into a Cul3-dependent 
ubiquitin ligase (E3) complex (Fig. 4) (Sekhar et al., 2002; McMahon et al., 2003; 
Wakabayashi et al., 2003; Kobayashi et al., 2004; Zhang et al., 2004; Furukawa and Xiong, 
2005; He et al., 2006). In the E3, Cul3 functions as a scaffold protein, where its N-terminal 
domain interacts with the BTB domain of Keap1 and its conserved C-terminal domain binds 
with RING box protein 1 (Rbx1). Rbx1 recruits the catalytic function of ubiquitin-
conjugating enzyme (E2) to the complex. Keap1 binds Nrf2 through its C-terminal DC 
domain and presents Nrf2 to Rbx1-bound E2 for polyubiquitination within the complex. 
Polyubiquitinated Nrf2 is then rapidly degraded by the 26S-proteasomes, resulting in a short 
half-life and a low protein level of Nrf2 in unstimulated cells (Fig. 4). The Keap1/Cul3/
Rbx1-E3 complex has an overall structure that is similar to those of the SCF complex and 
the ElonginC–Cul2–SOCS box complex, which catalyze the ubiquitination of inhibitor of 
NF-κB α and hypoxia inducible factor 1α, respectively (Ma, 2010).
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The chemical mechanism by which ARE inducers activate Nrf2 was suggested by Dinkova-
Kostova et al. (2001). By comparing inducers, they showed that a single and universal 
property of all inducers examined was reactivity with cysteine thiols at rates closely 
correlated with their potency for induction of NQO1. Binding of ARE inducers to Keap1 
cysteine thiols was demonstrated using tritium-labeled inducer, stoichiometry, UV 
spectroscopy, and mass spectrometry analyses of purified Keap1 (Dinkova-Kostova et al., 
2002). The most reactive residues of Keap1 were identified as Cys-257, Cys-273, Cys-288, 
and Cys-297, located in the IVR region between BTB and Kelch repeats of Keap1 (Fig. 5). 
These findings suggest that Keap1 serves as a cellular sensor through its reactive cysteine 
thiols, which recognize and interact with ARE inducers chemically by alkylation or 
oxidation, thereby transducing the signal for Nrf2 activation and gene induction.
Analyses of inducer-Keap1 interaction by several laboratories using mass spectrometry, 
mutagenesis, and mouse genetics identified a number of cysteine residues that are highly 
reactive to inducers and are important for activation of Nrf2 by ARE inducers or for 
suppression of Nrf2 under basal conditions (Eggler et al., 2005; Hong et al., 2005a,b; He and 
Ma, 2010). Highly reactive cysteine residues—including Cys-273, Cys-288, and Cys-297—
were consistently found in the IVR region (Fig. 5). Mutational studies revealed that 
Cys-151, Cys-273, and Cys-288 are important for regulation of Nrf2. Expression of the 
cysteine mutants in Keap1-null mice further confirmed that Cys-273 and Cys-288 are 
required for suppression of Nrf2 and Cys-151 for activation of Nrf2 by inducers (Yamamoto 
et al., 2008). In a Zebrafish model, electrophiles were shown to recognize distinct sets of 
cysteine residues of Keap1, coined as cysteine codes, to activate Nrf2 (Kobayashi et al., 
2009).
Unlike Keap1, which contains 25 to 27 cysteine residues, Nrf2 has only six (human Nrf2) or 
seven (mouse and rat Nrf2) cysteine residues that are highly conserved across species (Fig. 
5) (He and Ma, 2009). Two arsenic-based ARE inducers, FlAsH (a fluorophore) and 
phenylarsine oxide, bind to Nrf2 through interaction with its cysteine thiols. Further 
analyses revealed that Nrf2 cysteine residues have several functions in Nrf2 signaling, 
including induction of NQO1 by arsenic.
B. Structures of Nuclear Factor Erythroid 2-Related Factor 2 and Kelch-Like Erythroid Cell-
Derived Protein with CNC Homology-Associated Protein 1
Structural studies provided major insights into Nrf2-Keap1 interaction and Nrf2 signaling. 
The studies focused on two questions: How does Keap1 interact with Nrf2 for ubiquitination 
of Nrf2? How do ARE inducers inhibit this process?
Although the crystal structures of full-length Nrf2 and Keap1 are not available at the present 
time, major progress was made in structural resolution of the Nrf2 Neh2 domain, the Keap1 
DC domain with or without Nrf2 Neh2, and the full-length Keap1 homodimer structure. 
Nrf2 Neh2 (a.a. 1–98) is the primary binding structure of Nrf2 for interaction with Keap1. 
Neh2 contains three evolutionarily conserved motifs among the CNC proteins: an ETGE 
motif (a.a. 79–82, named after the four key amino acid residues), which is required for 
interaction with Keap1 (Kobayashi et al., 2002); a DLG motif (a.a. 29–31, named after the 
three key amino acid residues), which is important for ubiquitination and degradation of 
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Nrf2 (Katoh et al., 2005); and a DIDLID motif (a.a. 16–25, named after the six key amino 
acid residues), which is N-terminal to DLG and is involved in Nrf2 degradation, but acts as 
an activation domain in the Caenorhabditis elegans Nrf2 homolog SKN1 (Walker et al., 
2000; McMahon et al., 2004). Between DLG and ETGE is a hydrophilic region with seven 
lysine residues that are indispensable for Keap1-dependent polyubiq-uitination and 
degradation of Nrf2 (Zhang et al., 2004). NMR spectroscopy revealed that Neh2 is 
intrinsically disordered with local elements of secondary structures, including a 33-residue 
central α-helix (a.a. 39–71) followed by a mini antiparallel β-sheet (a.a. 74–76 and 82–85) 
(Tong et al., 2006). Of the seven lysine residues in the α-helix, six face one side of the helix. 
ETGE locates in the hydrophilic hairpin loop (Glu-78 to Gly-81) between the two mini β-
sheets. A tight β-hairpin conformation composed of Arg-25, Gln-26, Asp-27, Ile-28, and 
Asp-29 is located N-terminal to DLG (Tong et al., 2007).
Keap1 is one of the BTB-Kelch proteins that are named after the D. melanogaster Kelch 
protein and consist of more than 50 members encoded by the human genome. The consensus 
Kelch repeat motif contains several highly conserved residues, including two adjacent 
glycine residues and a tyrosine/tryptophan pair separated by exactly seven residues (Bork 
and Doolittle, 1994). The structure of the human Keap1 Kelch domain (a.a. 321–609) was 
resolved by crystallography at a 1.85 Å resolution. The Kelch domain folds up into a six-
bladed β-propeller structure and uses a C-terminal strand mechanism of closure; i.e., 
residues of the C terminus form the first strand of the first blade (Li et al., 2004c). The 
conserved tyrosine/tryptophan pairs participate in interblade interactions, and the glycine 
doublets contribute to a conserved hydrogen-bonding network within each blade. In a 
separate study, the mouse Keap1 DC domain (a.a. 309–624, consisting of the Kelch/DGR 
and the CTR domains) was structurally resolved by crystallography at 1.60 Å (Padmanabhan 
et al., 2006). The overall tertiary structure is a drum-shaped, β propeller structure similar to 
the Kelch structure described for human Keap1. An inner cavity buried in the central core 
has a strong hydrophobic character, opening on the top with a diameter of approximately 15 
Å and on the bottom, 9.5 Å.
The overall structure of mouse Keap1 was examined by using single-particle electron 
microscopy and three-dimensional reconstruction at a 24-Å resolution. Keap1 is a dimer 
consisting of two large globular structures attached by short linker arms to the sides of a 
small forked-stem structure, resembling a cherry-bob (Ogura et al., 2010). Each globular 
domain is a vertically elongated sphere with dimensions of 60 × 60 × 78 Å3, and each has a 
tunnel corresponding to the central core of the β-propeller structure in the crystal structure of 
Kelch or DC domain. The stem-shaped central region comprises two thin, interacting layers 
separated by a narrow gap, reflecting the dimerization interface between two Keap1 
monomers through the BTB domain; this dimeric interface is in agreement with a previous 
finding that BTB is required for Keap1 dimerization and function (Zipper and Mulcahy, 
2002). Comparison of the three-dimensional Keap1 dimer structure with the theoretical mass 
ratio of the Keap1 domains deduced from the primary amino acid sequences (i.e., BTB, 
28%; IVR, 23%; DC, 49%) suggested that the stem region (13.5% of the total volume) is 
part of the BTB domain, whereas the globular spheres (86.5% of the total volume) consist 
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mostly of the IVR and DC domains with IVR on the outer surface and DC in the interior of 
the spheres.
C. A Two-Site Binding Model
Isothermal calorimetry and NMR titration analyses first suggested that one Neh2 domain of 
Nrf2 interacts with two molecules of Keap1 through its ETGE and DLG motifs (Tong et al., 
2006). Both ETGE and DLG bind to similar sites on the bottom surface of the β-propeller 
structure of Keap1 DC. However, the binding affinity of ETGE is 2 orders of magnitude 
higher than that of DLG. The central α-helix between ETGE and DLG of Neh2 serves as a 
bridge connecting the two motifs in the association with two Keap1 DC spheres. This spatial 
relationship among the ETGD, α helix, DLG of Neh2, and the two DC of Keap1 is in a good 
agreement with the dimeric cherry-bob structure of Keap1 obtained from single-particle 
electron microscopy, where the distance between the two binding pockets of Keap1 dimer 
roughly equals the distance between ETGE and DLG of Neh2 (i.e., ~80 Å). (Ogura et al., 
2010).
The crystal structures of human Keap1 Kelch domain bound with Nrf2 ETGE motif and 
mouse Keap1 DC domain bound with either ETGE or DLG revealed the interaction between 
Nrf2 and Keap1 at the binding interface in more details (Lo et al., 2006; Padmanabhan et al., 
2006; Tong et al., 2007). The binding cleft of Keap1 DC resides at the entrance of the 
central cavity on the bottom of the β-propeller structure. ETGE and DLG interact with 
Keap1 in a very similar manner: both adopt a tight β-turn conformation and orient in 
essentially the same manner with respect to the Keap1 DC structure. However, the ETGE 
motif has more electrostatic interactions (~13) with Keap1 DC than the DLG motif has (~8), 
and ETGE is more deeply embedded into the Keap1 DC binding cleft compared with DLG-
DC binding, accounting for the large difference between the binding affinities of the motifs 
for Keap1 DC (Tong et al., 2007).
These studies provided a structural basis for a two-site binding model for the control of Nrf2 
ubiquitination by Keap1. Under a basal condition, Keap1 recruits newly synthesized Nrf2 
protein to the Keap1/Cul3/Rbx1-E3 complex by binding to Nrf2 through Keap1 DC-Nrf2 
Neh2 interaction and to Cul3 through Keap1 BTB-Cul3 N terminus interaction. Nrf2 Neh2 
takes a rod-like shape. Because of its higher binding affinity, the ETGE motif binds to one 
of the dimeric Keap1 globular subunits at the bottom binding cleft of DC as the first step. 
Binding of ETGE promotes binding of DLG to the other DC sphere at a similar binding 
surface. This “hinge and latch” mode of binding positions the lysine residues in the α-helix 
between DLG and ETGE to the E2 enzyme recruited by Rbx1 for polyubiquitination. 
Ubiquitinated Nrf2 is then rapidly degraded by the 26S proteasomes resulting in a short half-
life of Nrf2 protein. It is noteworthy that, although the majority of synthesized Nrf2 proteins 
are degraded rapidly, a small pool of Nrf2 accumulates in the nucleus to mediate a low, but 
detectable, basal expression of ARE-controlled NQO1 and GSTs (Fig. 4).
The molecular mode of action for inhibition of Nrf2 ubiquitination by ARE inducers is not 
well understood. Several mechanisms have been proposed. First, the two-site binding model 
predicts that modification of critical cysteine thiols of the IVR domain, which are close to 
the DC domain in the globular structure, provokes dissociation of DLG from DC (the latch) 
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but not ETGE from DC (the hinge) binding, because DLG-DC binding is much weaker than 
ETGE-DC binding. This conformation of the complex prevents Nrf2 from ubiquitination, 
even though Nrf2 remains in the complex. The observation supporting this model is that 
some inducers, such as phenolic antioxidant tBHQ, failed to disrupt Nrf2-Keap1 binding at 
concentrations at which Nrf2 was activated and ARE-dependent genes were induced (He et 
al., 2006; Kobayashi et al., 2006). In this scenario, the inducer-modified and Nrf2-bound 
Keap1 is inactivated and, consequently, newly synthesized Nrf2 proteins bypass Keap1 and 
translocate into the nucleus to mediate induction of ARE-dependent genes. Second, some 
inducers, such as metal inducers As3+, Cd2+, and Cr6+, are capable of disrupting Nrf2-Keap1 
binding as revealed by loss of coimmunoprecipitation of Nrf2 and Keap1 at inducing 
concentrations; this finding suggests that the metal inducers release Nrf2 from the Keap1/
Cul3/Rbx1-E3 complex to activate Nrf2 (He et al., 2006, 2007, 2008). Third, modification 
of certain Keap1 cysteines close to the interface between Keap1 and Cul3, such as Cys-151 
in the BTB domain, may disrupt the Keap1-Cul3 interaction, thereby preventing Nrf2 from 
ubiquiti-nation by E3.
The close proximity of BTB Cys-151 to Keap1-Cul3 interaction and IVR Cys-273 and 288 
to Keap1 DC-Nrf2 Neh2 interaction supports the above mechanisms. However, it has been 
difficult to dissect the exact role of individual cysteine residues in the control of Nrf2 
activation for several reasons. For example, detailed structural information of the 25 to 27 
cysteines of Keap1 and the six to seven cysteines of Nrf2 in the E3 complex is not available 
at the present time. Multiple cysteine residues are often modified by any given inducer. 
Cysteine residues of Keap1 and Nrf2 often have multiple and overlapping functions that 
include maintenance of tertiary structure, DNA-binding, and transcription activation, in 
addition to chemical sensing and ubiquitination of Nrf2 under basal conditions. Therefore, 
identification of the cysteine codes for different inducers and resolution of the three-
dimensional structure of the quaternary Nrf2-Keap1-Cul3-Rbx1 complex to reveal the 
spatial arrangement of each component and individual cysteine residues would help 
elucidate the mechanism by which ARE inducers activate Nrf2 at a molecular level.
D. Other Mechanisms of Nuclear Factor Erythroid 2-Related Factor 2 Signaling
In addition to cysteine thiol modification by inducers, several other mechanisms have been 
described to regulate Nrf2 signaling in a cell type-, target gene-, and disease-dependent 
manner.
1. Suppression of Kelch-Like Erythroid Cell-Derived Protein with CNC 
Homology-Associated Protein 1 by Disrupter Proteins—Autophagy is a conserved 
protein degradation pathway responsible for the disposal of long-lived proteins, excess or 
damaged organelles, and aggregation-prone proteins. The p62 protein is a selective substrate 
for autophagy and a regulator of protein aggregate formation. Loss of autophagy in mice 
caused marked accumulation of p62 accompanied with liver injury and robust induction of 
antioxidant proteins including NQO1 and GSTs (Komatsu et al., 2007, 2010). This finding 
suggests that p62 serves as an endogenous protein inducer of Nrf2 target genes. p62 binds to 
Keap1 through its KIR motif, which binds to the bottom basic surface pocket of Keap1 
overlapping with the binding pocket for Nrf2 ETGE and DLG. The KIR motif (a.a. 345–
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359) of p62 contains a STGE sequence (a.a. 351–355) that mediates binding of p62 to 
Keap1 at the “latch” site with a binding affinity similar to that of Nrf2 DLG-Keap1 DC 
binding. Excessive buildup of p62 leads to suppression of Keap1 by inhibiting Nrf2 DLG-
Keap1 binding leading to activation of Nrf2 and induction of ARE-dependent genes (Jain et 
al., 2010; Komatsu et al., 2010; Lau et al., 2010). Thus, p62 is a disruptor of Nrf2-Keap1 
binding. Loss of Nrf2 alleviated, but loss of Keap1 exacerbated the liver injury observed in 
autophagy-deficient mice, revealing a role of Nrf2-Keap1 dysregulation in autophagy-
related pathologic liver conditions.
The cyclin-dependent protein kinase p21 (Cip1/WAF1) is a target gene of p53 and is up-
regulated in response to oxidative stress to protect cells from oxidative damage. The 
antioxidant function of p21 was suggested to be mediated through activation of Nrf2 (Chen 
et al., 2009b). In this scenario, p21 acts as a disrupter protein of Nrf2-Keap1 binding. The 
basic tripeptide KRR (a.a. 154–156) of p21 directly interacts with the DLG and ETGE 
motifs of Nrf2, thereby competing with Keap1 for Nrf2 binding to suppress Nrf2 
ubiquitination and degradation.
2. Kelch-Like Erythroid Cell-Derived Protein with CNC Homology-Associated 
Protein 1-Independent Degradation of Nuclear Factor Erythroid 2-Related 
Factor 2 Signaling—The Neh6 domain (a.a. 331–381) of Nrf2 was shown to mediate 
degradation of Nrf2 under redox stress conditions under which Keap1 was inhibited, 
implying that Nrf2 can be degraded through a Keap1-independent mechanism (McMahon et 
al., 2004). The redox-insensitive degron contains multiple serine residues at 335, 338, 342, 
347, 351, and 355 positions of mNrf2, which can be phosphorylated by glycogen synthase 
kinase 3 (GSK-3) and, possibly, other kinases (Rada et al., 2011). Phosphorylaton of 
Ser-335 and Ser-338 in a conserved DSGIS (a.a. 334–338) sequence of Nrf2 by GSK-3 
creates a recognition motif DpSGX(1–4)pS, which is recognized by the WD substrate 
recognition domain of β-transducin repeat-containing protein, an adaptor protein for the 
Cul1-dependent SCF E3 complex. β-Transducin repeat-containing protein brings Nrf2 into 
the SCF E3 complex by binding to Skp1 through its F-box domain and promotes the 
ubiquitination and subsequent proteasomal degradation of Nrf2 in a manner similar to the 
ubiquitination and degradation of IκBα. It was postulated that this PI3K/Akt-GSK-3-
regulated, redox-insensitive degradation pathway of Nrf2 has certain implications in 
neurodegenerative pathology and, perhaps, the aging process (Rada et al., 2011).
3. Modulation of Nuclear Factor Erythroid 2-Related Factor 2 Signaling-
Dependent Transcription—Some bZip proteins—such as Nrf1, Bach proteins, AP-1 
proteins, and CCAAT/enhancer-binding protein—may directly interfere with Nrf2-
dependent transcription. Nrf1 and Bach proteins can heterodimerize with small Mafs and 
bind to ARE enhancers, whereas AP-1 proteins and CCAAT/enhancer-binding protein bind 
to TRE or cAMP response element within composite ARE sequences. A number of other 
proteins—including ATF3, ERα, peroxisome proliferator-activated receptor γ, RARα, NF-
κB, and p53—can antagonize Nrf2 for induction of ARE-dependent genes through various 
mechanisms. ATF3 is a member of cAMP response element-binding proteins; ATF3 
suppresses Nrf2-mediated transcription of ARE-dependent genes by dimerizing with Nrf2 
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and binding to AREs located in the proximal promoters of Nrf2 target genes, which 
suppresses recruitment of CBP (Brown et al., 2008). NF-κB may also antagonize Nrf2 by 
depriving CBP from Nrf2 (Liu et al., 2008a). The estrogen 17β-estradiol suppresses ARE-
dependent DMEs; estrogen-bound ERα is coimmunoprecipitated with Nrf2, suggesting a 
direct interaction of ligand-activated ERα with Nrf2 that suppresses ARE-dependent gene 
induction (Ansell et al., 2005). All-trans retinoic acid suppresses Nrf2-mediated ARE 
induction by activating RARα to form a complex with Nrf2, whereas vitamin A deficiency 
up-regulates ARE-dependent gene expression by inhibiting RARα (Wang et al., 2007).
4. Phosphorylation—A number of protein kinases have been reported to phosphorylate 
Nrf2 in response to different stressors, including casein kinase 2, PKC, GSK, c-Jun NH2-
terminal kinase, protein kinase RNA-like endoplasmic reticulum kinase, 
phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase (Nguyen et al., 
2003). The human Nrf2 exhibits two bands on SDS-polyacrylamide gel electrophoresis: the 
lower band corresponds to the unphosphorylated form, whereas the upper band is due to 
phosphorylation of Nrf2 by casein kinase 2 in the transcription activation domain, which 
promotes the nuclear translocation and transcription activation of Nrf2 (Apopa et al., 2008). 
Phorbol esters stimulate transcription of ARE-dependent genes, suggesting a role of PKC 
(Nguyen et al., 1994). The PKC-catalytic subunit and PKC immunoprecipitated from cells 
could directly phosphorylate Nrf2 in vitro at Ser-40; moreover, tBHQ-induced 
phosphorylation and nuclear localization of Nrf2 were inhibited by PKC inhibitors (Huang 
et al., 2000, 2002; Bloom and Jaiswal, 2003; Numazawa et al., 2003). The tyrosine kinase 
Fyn phosphorylates Tyr-568 to allow Nrf2 nuclear export through Crm1 for degradation in 
the cytoplasm (Jain and Jaiswal, 2006). In addition to promoting degradation of Nrf2 
through SCF-E3, phosphorylation of Nrf2 by GSK-3β localizes Nrf2 to the cytoplasm, 
providing another means of inhibiting ARE transcription by Nrf2 through the 
phosphatidylinositol 3/Akt pathway (Salazar et al., 2006). The mitogen-activated protein 
kinase signaling pathways were also implicated in the regulation of Nrf2 (Nguyen et al., 
2003). It is generally believed that these signaling pathways modulate Nrf2 activation steps, 
such as nuclear translocation and transcription activation, in cell type- and gene-specific 
manner, but do not replace the Keap1-dependent ubiquitination and degradation of Nrf2 as 
the primary mechanism of Nrf2 regulation.
5. Acetylation/Deacetylation—In addition to acting as a coactivator of Nrf2, CBP 
promotes acetylation of Nrf2, which is associated with nuclear localization, increased 
binding to ARE, and increased transcription by Nrf2 (Kawai et al., 2011). On the other hand, 
sirtuin 1 decreases acetylation of Nrf2, and deacetylation of Nrf2 results in the nuclear 
export and cytoplasmic localization of Nrf2.
IV. Nuclear Factor Erythroid 2-Related Factor 2 Signaling in Disease and 
Toxicity: Expecting the Unexpected
Parallel to the remarkable progress in the understanding of the mechanism of Nrf2 signaling 
during the past decade was the rapid accumulation of a body of knowledge on the function 
of the Nrf2-ARE pathway. Investigations using knockout mouse models, gene arrays, 
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mutations and polymorphisms, and new inducers have revealed the involvement of Nrf2 in a 
surprisingly broad range of physiologic and disease processes.
A. Carcinogenesis
The Nrf2 knockout mice served as a genetic model for testing the importance of Nrf2 in 
chemical carcinogenesis, which was predicted from the chemopreventive effects of ARE 
inducers. The first carcinogen examined was Bp (Ramos-Gomez et al., 2001). Treatment of 
mice with Bp induced tumors in the forestomach, but the Nrf2 knockout mice showed a 
significantly higher burden of gastric tumors than wild type. The number of tumors in the 
forestomach per mouse was 9.5 ± 1.0 for wild type and 14.1 ± 1.2 for knockout mice (p = 
0.003). Consistent with the results, constitutive hepatic and gastric activities of GST and 
NQO1 were reduced by 50 to 80% in Nrf2-null mice compared with wild type. To evaluate 
the impact of Nrf2 genotype on Bp bioactivation and disposition, levels of Bp-DNA adducts 
were measured as tetrols released from DNA isolated from target (forestomach) and 
nontarget tissues (liver) of wild-type and Nrf2-null mice treated with Bp (Ramos-Gomez et 
al., 2003). Levels of Bp-DNA adducts in the forestomach, but not in the liver, were 
significantly higher in Nrf2-null mice than in wild type. Together, these findings provided 
direct evidence supporting an important role of Nrf2 in protection against Bp carcinogenesis 
through controlling the expression of ARE-dependent genes and Bp-DNA adduct 
disposition.
Nrf2-null mice were susceptible to urinary bladder cancer induced by N-nitrosobutyl(4-
hydroxybutyl)amine (BBN) (Iida et al., 2004). The incidence of urinary bladder carcinoma 
by BBN was significantly higher in Nrf2-null mice than in wild type; invasive carcinoma 
was 24% for the wild type but 38.5% for the knockout mice. Oltipraz effectively inhibited 
BBN-induced bladder cancer. Crossing Nrf2-null and p53 knockout mice [Nrf2(−/−)::p53(+/
−)] significantly increased susceptibility of the mice to BBN-induced urinary bladder cancer 
compared with wild-type, Nrf2-null, and p53(+/−) phenotypes individually (Iida et al., 
2007). BBN increased p53-mediated expression of p21, Mdm2, and Bax, and the inducible 
expression of p21 was significantly increased in Nrf2-null mice. On the other hand, urinary 
concentrations of N-nitrosobutyl(3-carboxy-propyl)amine, a proximate carcinogen of BBN, 
were increased in Nrf2-null, but not p53(+/−), mice. Modest increases in NQO1 and 
UGT1A6 expression were observed in p53(+/−) mice compared with wild type after BBN 
exposure. These results demonstrate that tumor susceptibility is synergistically exacerbated 
in Nrf2- and p53-deficient mice in comparison with either mutation alone as a result of poor 
detoxification and accelerated proliferation.
Nrf2 deficiency also increased sensitivity of mice to several other cancer models. Treatment 
with 7,12-dimethylbenz(a)anthracene and TPA resulted in an increase in the incidence of 
skin tumors as well as tumor numbers per mouse in wild-type and Nrf2 knockout mice; 
however, both indices were markedly higher in Nrf2-null mice than in wild type (Xu et al., 
2006). In a mouse model of azoxymethane/DSS-induced colorectal carcinogenesis, Nrf2 
knockout mice showed increased incidence, multiplicity, and size of all colorectal tumors 
compared with wild type upon treatment; the proportion of adenocarcinoma was much 
higher in knockout (80%) versus wild-type (29%) mice (Khor et al., 2008). Using the Nrf2-
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deficient gpt delta mice, which lack Nrf2 but harbor a transgenic guanine 
phosphoribosyltransferase gene (a target gene for assessing genotoxicity in vivo), Nrf2 was 
shown to protect against spontaneous and Bp-induced mutations in the lungs of the mice 
(Aoki et al., 2007).
Nrf2 affects tumor progression and metastasis. Susceptibility of Nrf2-deficient mice to 
pulmonary cancer metastasis was investigated after implantation of the mouse Lewis lung 
carcinoma cell line. Nrf2-null mice reproducibly exhibited a higher number of pulmonary 
metastatic nodules than wild-type mice, indicating that Nrf2 inhibited cancer metastasis in 
the lungs, presumably by preserving the redox balance in the hematopoietic and immune 
systems (Satoh et al., 2010). Treatment with 7,12-dimethylbenz(a)anthracene and 
medroxypro-gesterone acetate induced premalignant lesions and mammary carcinomas in 
mice. Although no apparent difference in the formation of the premalignant lesions was 
observed between Nrf2 knockout and wild-type mice, the knockout mice exhibited rapid and 
aggressive mammary carcinoma progression (Becks et al., 2010).
A few recent studies indicate that Nrf2 promotes tumorigenesis in certain models of cancer, 
suggesting that the role of Nrf2 in cancer varies depending on the context in which the 
tumor was induced. Targeted deletion of Nrf2 in mice reduced urethane-induced lung tumor 
formation compared with wild-type mice, revealing that Nrf2 is activated in wild-type mice 
to confer resistance to anticancer agents and promote malignancy (Bauer et al., 2011). 
Expression of endogenous oncogenic alleles of Kras, Braf, and Myc suppressed ROS by 
activating the Nrf2 antioxidant program, indicating that the Nrf2-mediated antioxidant and 
cellular detoxification functions are involved in oncogenesis by oncogenes (DeNicola et al., 
2011). As discussed later, some cancers overactivate Nrf2 through somatic mutations and 
epigenetic mechanisms to result in a prosurvival phenotype for tumor growth.
B. Chemical Toxicity
Loss of Nrf2 in mice substantially increases sensitivity of the mice to a wide range of acute 
and chronic chemical toxicity. The first chemical tested for toxicity in Nrf2-null mice was 
butylated hydroxytoluene (BHT), a food additive used to prevent lipid peroxidation in meat. 
BHT treatment by either systemic or oral administration caused transient lung damage with 
destruction of alveolar type I epithelial cells, massive edema, and hemorrhage that generally 
recover within 7 days of exposure. However, when treated with BHT at doses that were well 
tolerated by wild-type mice, the Nrf2-null mice succumbed from a severe acute respiratory 
distress syndrome with a high rate of mortality (Chan and Kan, 1999). When fed with 1% 
BHT in diet, 80% of Nrf2-null mice died, whereas the wild-type mice were resilient to the 
diet with only transient general toxicity. The profound sensitivity to BHT lung toxicity 
observed in Nrf2 knockout mice was attributed to reduced detoxification of the toxicant in 
the intestine, liver, and kidneys and type II alveolar epithelial cells in the lungs.
The impact of Nrf2 knockout on acetaminophen hepatotoxicity exemplifies the multiple 
roles of the Nrf2-ARE pathway on chemical toxicity. At doses well tolerated by wild-type 
mice, Nrf2 knockout mice developed centrilobular hepatocellular necrosis with elevated 
levels of plasma alanine aminotransferase activity; homozygous Nrf2-null mice died of liver 
failure in severe cases (Chan et al., 2001; Enomoto et al., 2001). On the other hand, mice 
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with hepatocyte-specific disruption of Keap1, which caused constitutive activation of Nrf2 
and elevated expression of NQO1 and GSTs, showed remarkable resistance to lethality by 
high doses of acetaminophen (Okawa et al., 2006). In addition, induction of GSTs by ARE 
inducers were effective in inhibition of acetaminophen toxicity (Ansher et al., 1983; 
Reisman et al., 2009a). The mechanism by which Nrf2 protected mice from acetaminophen 
hepatotoxicity was severalfold. Acetaminophen caused depletion of GSH in the liver of both 
wild-type and knockout mice; however, the wild-type mice were able to compensate and 
regain the normal GSH level, whereas the knockout mice failed to do so because of 
decreased synthesis of GSH (Chan et al., 2001). The effect of Nrf2 on the pharmacokinetics 
of acetaminophen in mice was examined in wild-type, Nrf2-null, and heterozygous Keap1 
knockout mice using a subtoxic dose (50 mg/kg) (Reisman et al., 2009b). Loss of Nrf2 
caused reduction of glucuronidation of acetaminophen as well as efflux of acetaminophen-
glucuronide conjugate via multidrug resistance-associated protein 3. On the other hand, 
activation of Nrf2 by knocking out Keap1 in the liver resulted in increased elimination of 
acetaminophen-glucuronide conjugate as a result of increased expression of multidrug 
resistance-associated protein 3.
Many other chemicals were studied for toxicity using Nrf2 knockout mice, where Nrf2 was 
shown to be protective against the acute and chronic toxicities of the chemicals. Examples 
include acute and chronic carbon tetrachloride liver injury (liver necrosis, inflammation, and 
fibrosis) (Xu et al., 2008), metal toxicity (arsenic, cadmium, and chromium) (He et al., 2006, 
2007, 2008; Jiang et al., 2009), diesel exhaust particle-induced inflammatory and oxidative 
damage in bronchial epidermis (Aoki et al., 2001; Li et al., 2004b), and lipopolysaccharide-
induced sepsis (Thimmulappa et al., 2006). Nrf2 also protected against neurotoxicant-
induced toxicity to neurons, glial cells, and peripheral nervous tissues, including 3-
nitropropionic acid and malonate-induced striatal damage, which involves inhibition of 
mitochondrial respiratory chain complex II (Calkins et al., 2005), kainic acid-induced 
hippocampal neuron damage and seizure (Kraft et al., 2006), and 6-hydroxydopamine-
induced cell loss in the substantia nigra and striatal dopamine depletion (Jakel et al., 2007).
C. Disease Pathologic Features
1. Spontaneous Lesions—Although the initial characterization of Nrf2 knockout mice 
showed that the mice developed normally and mature to reproduce, later studies revealed 
some spontaneous lesions. Female Nrf2-null mice showed a tendency to develop multiorgan 
autoimmune inflammation and glomerulonephritis, especially in aged mice (Yoh et al., 
2001; Li et al., 2004a; Ma et al., 2006). The mice exhibited increased proliferation of CD4+ 
T cells, elevated ratio of CD4+ to CD8+ cells, and escalated oxidative damage in tissues, 
linking Nrf2 functions to peripheral lymphocyte homeostasis and autoimmune surveillance. 
The Nrf2 knockout mice also developed splenomegaly and regenerative immune-mediated 
hemolytic anemia, in which chronic oxidative stress may sensitize erythrocytes to cause 
hemolysis (Lee et al., 2004). Nrf2-null mice showed vacuolar (spongiform) type of 
leukoencephalopathy with widespread astrogliosis in the brain, suggesting a physiological 
function for Nrf2 in the maintenance of the central nervous system myelin structure and 
function (Hubbs et al., 2007). It is noteworthy that conditional knockout of Nrf1 in mouse 
brain using the Cre-Lox technology caused age-dependent neurobehavioral abnormalities 
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and brain atrophy as a result of apoptosis of the cortex (Kobayashi et al., 2011; Lee et al., 
2011). Moreover, the mice showed loss of neurons in the hippocampal area and increased 
accumulation of polyubiquitinated proteins in brain regions, partly because of reduced 
expression of certain components of the 26S proteasome. The genes encoding the 
proteasome proteins have ARE enhancers, and Nrf1 up-regulates the expression of the genes 
by binding to the AREs in a similar fashion to Nrf2 (Lee et al., 2011).
2. Induced and Genetic Disease Models—Nrf2-deficient mice are susceptible to 
induced or genetic models of diseases involving the respiratory, neuro, immune, 
reproductive, and metabolic functions. Bleomycin, an antibiotic type of anticancer drug, 
causes pulmonary fibrosis in susceptible patients with cancer. Bleomycin induced lung 
lesions and fibrosis with increased hydroxyproline content, collagen deposition, fibrotic 
score, and cell proliferation more significantly in Nrf2-null mice than in wild type (Cho et 
al., 2004). Consistent with these findings, bleomycin activated Nrf2 and induced ARE-
dependent genes in wild-type but not knockout mice, accounting for a protective role of 
Nrf2 in lung fibrosis in wild-type mice. Cigarette smoking increases the oxidative burden in 
the lungs and causes emphysema, a progressive and destructive lung disease associated with 
chronic obstructive pulmonary disorder. In comparison with wild-type mice, Nrf2-deficient 
mice developed early onset and extensive emphysema upon exposure to cigarette smoke for 
6 months (Rangasamy et al., 2004). Ovalbumin sensitization and challenge caused severe 
airway inflammation and hyper-responsiveness that was marked with pronounced mucus 
cell hyperplasia and infiltration of eosinophils in Nrf2-deficient mice compared with wild-
type litter-mates (Rangasamy et al., 2005). Hyperoxia (>95% oxygen) causes acute lung 
injury by generating ROS. Nrf2 was identified as a candidate gene associated with increased 
susceptibility to hyperoxia in mice through a genome-wide lineage analysis (Cho et al., 
2002b). Exposure of Nrf2 knockout mice to hyperoxia resulted in more severe pulmonary 
injury and inflammation than wild-type control mice, confirming a protective role of Nrf2 
against lung toxicity of hyperoxia (Cho et al., 2002a).
Dominant mutations in superoxide dismutase 1 cause familial amyotrophic lateral sclerosis, 
a progressive and fetal neurodegenerative disease characterized by progressive loss of motor 
neurons. Overexpressing Nrf2 in astrocytes was protective against mutant human super-
oxide dismutase1-induced toxicity to neurons. Protection was also observed by crossing 
mice that overexpress Nrf2 with two amyotrophic lateral sclerosis mouse models. In both 
cases, overexpression of Nrf2 significantly delayed the onset of disease and extended 
survival of the mice (Vargas et al., 2008). MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) causes oxidative damage and Parkinson’s disease-like lesions in mouse 
brain. Nrf2 deficiency increased the sensitivity of mice to MPTP-induced lesions; on the 
other hand, overexpression of Nrf2 in astrocytes abolished MPTP toxicity (Chen et al., 
2009a).
Multiple sclerosis is an autoimmune disease in which peripherally activated CD4+ T cells 
migrate into the central nervous system to mount autoimmune attack on myelin and 
oligodendrocytes. When Nrf2-null mice were immunized with myelin oligodendrocyte 
glycoprotein (MOG 35–55), the mice developed experimental autoimmune 
encephalomyelitis, an acute model of multiple sclerosis, which was more severe and more 
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rapidly onset than in wild-type control mice (Johnson et al., 2010). The finding is in 
agreement with the notion that the Nrf2-ARE pathway modulates immune functions in vivo.
Female mammals are born with primordial follicles in the ovaries. Activation of resting 
follicles occurs through an unknown triggering mechanism intrinsic to the ovary and 
independent of pituitary gonadotropins. Depletion of ovarian follicles through atresia during 
aging causes ovarian failure (menopause). Infertility secondary to early follicular depletion 
in women younger than 40 is defined as premature ovarian failure. VCD (4-
vinylcyclohexene diepoxide) is a metabolite of 4-vinylcyclohexene, an occupational by-
product from the dimerization of 1,3-butadiene. VCD selectively damages small follicles in 
the ovary and causes ovarian cancer in rodents (Hoyer and Sipes, 1996). VCD destroyed 
small follicles by ~50% in wild-type mice, but depleted the follicles by 95% in Nrf2-
deficient mice (Hu et al., 2006). The knockout mice exposed to VCD developed premature 
ovarian failure by 30 weeks of age compared with 50 weeks for the wild-type control mice. 
Follicle depletion correlated with diminished expression of microsomal epoxide hydrolase in 
the liver and Foxo3a in the ovaries as well as elevated oxidative stress and apoptosis in the 
ovaries of Nrf2-null mice.
V. Genetics and Cancer Mutation: Revealing the Perilous Side of Nuclear 
Factor Erythroid 2-Related Factor 2 Signaling Activation
A. Genetic Activation of Nuclear Factor Erythroid 2-Related Factor 2 Signaling in Mice
Knockout of the Keap1 gene in mice caused lethality within 3 weeks after birth. The 
weaning mice died from malnutrition due to hyperkeratinization and occlusion of the 
esophagus and forestomach (Wakabayashi et al., 2003). Nrf2 was constitutively activated, 
and Nrf2 activity affected the expression of several keratinocyte-specific genes in the mice. 
Crossing Keap1-null mice with the Nrf2-null mice reversed Keap1-deficiency phenotypes. 
These findings imply that persistent activation of Nrf2 has a detrimental effect on the 
development of the digestive system. Conditional knockout of Keap1 was generated to 
circumvent the postnatal lethality by generating floxed alleles of the Keap1 gene and 
hepatocyte-specific deletion of Keap1 by crossing the floxed-Keap1 mice with transgenic 
mice expressing Cre recombinase under the regulation of the Albumin gene (Alb-Cre mice) 
(Okawa et al., 2006). These mice showed reduced Keap1 activity but elevated Nrf2 function 
and increased expression of ARE-dependent genes, and they were resistant to toxicity in 
several models, including acetaminophen hepatotoxicity (Okawa et al., 2006), concanavalin 
A inflammatory liver injury (Osburn et al., 2008), and bile duct ligation-induced cholestasis 
(Okada et al., 2009). Floxation of the Keap1 allele in the mice caused a partial disruption of 
Keap1 expression, creating Keap1 knockdown. Reduced expression of Keap1 and 
subsequent activation of Nrf2 in the mice conferred resistance against acute toxicity of 
acetaminophen, as expected; however, a decrease in Keap1 levels to less than 50% of that in 
control mice resulted in increased mortality in a study of 2-year-old mice, indicating that the 
benefits of Nrf2 activation are context-dependent, and persistent activation of Nrf2 
exceeding a certain threshold is harmful to survival (Taguchi et al., 2010).
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B. NRF2 Mutation in Cancer
Early studies revealed that expression of GSTs (GST P1, GST A2) and NQO1 was highly 
elevated in preneoplastic nodules compared with surrounding normal tissues in the liver 
chemical carcinogenesis model. Elevated expression of GSTs and NQO1 were also observed 
in tumor cell lines and liver, lung, colon, and breast tumors compared with normal tissues of 
the same origin. These findings led to the concept that cancer cells evolve to develop 
resistance to cancer-killing agents by overexpressing cytoprotective enzymes (Farber, 1984; 
Kitahara et al., 1984; Cowan et al., 1986; Belinsky and Jaiswal, 1993). Recent 
characterization of NRF2 and KEAP1 gene mutations in human cancers provided new 
insights into Nrf2 function in tumors. In two separate studies, mutations of the NRF2 gene 
were found in 6 to 25% of the human cancers examined. In one study, mutations were 11 of 
103 (11%) in primary lung cancer and 3 of 12 (25%) in primary head and neck cancer 
(Shibata et al., 2008b); whereas, in the other study, mutations were 10 of 125 (8%) in lung 
cancer, 3 of 23 (13%) in head and neck cancer, 6 of 70 (11%) in esophageal cancer, and 1 of 
17 (6%) in skin cancer (Kim et al., 2010). Most mutations were found within the ETGE 
(57%) and DLG (43%) motifs, which caused disruption of the low-affinity DLG-DC 
interaction or the high-affinity ETGE-DC binding, either of which inhibits the ubiquitination 
of Nrf2 to result in the activation and accumulation of Nrf2. The NRF2 mutations were 
mostly heterozygous and were associated with squamous cell carcinoma (77%), a smoking 
history (79%), lower incidence of simultaneous epidermal growth factor receptor mutations, 
and poor prognosis.
C. KEAP1 Mutation in Cancer
Mutations of the KEAP1 gene in cancer involving missense mutations and amino acid 
substitutions can lead to impaired Keap1 function (Padmanabhan et al., 2006; Singh et al., 
2006; Nioi and Nguyen, 2007; Ohta et al., 2008; Shibata et al., 2008a; Takahashi et al., 
2010). The mutations were mostly found in the DC domain (65%), followed by IVR (29%), 
BTB (3%), and the N-terminal region (3%), and were frequently associated with 
adenocarcinomas. Lung and prostate cancer cells also have reduced expression of Keap1 as 
a result of increased DNA methylation at the KEAP1 promoter (Wang et al., 2008; Zhang et 
al., 2010). These mutations and reduced expression of Keap1 resulted in constitutive 
stabilization of Nrf2 protein and persistently elevated expression of ARE-dependent 
cytoprotective genes.
The findings from Keap1 knockout and human cancer mutation studies led to the emerging 
view that—like any biological defense systems, such as inflammation, immune reaction, and 
DNA damage repair—the Nrf2-ARE pathway is a double-edged sword (Fig. 4)(Kensler and 
Wakabayashi, 2010; Taguchi et al., 2011). In normal cells under most conditions, Nrf2 is 
protective for the whole body, inhibiting both tumor initiation and cancer metastasis by 
eliminating carcinogens, ROS, and other DNA-damaging agents. On the other hand, 
persistently elevated activity of Nrf2 may be advantageous to single cancer cells for survival 
and resistance to ROS, anticancer drugs, and stress. It is believed that increased 
representation of Nrf2 and Keap1 mutations and elevated expression of ARE-dependent 
genes in cancer cells are the result of selection during tumor development rather than a 
cancer-initiating event, because knockdown of Keap1 in mice resulted in constitutive 
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activation of Nrf2 but did not cause cancer over a 2-year period of time (Taguchi et al., 
2010).
D. Human Polymorphism
Individual variability in the response to drugs, environmental insults, and disease signals in 
humans is a major challenge in today’s medicine and risk evaluation. Given the role of the 
Nrf2-ARE pathway as a major defense system in the body, individual variations of the 
pathway would contribute to such variability in human populations. Both genetic 
polymorphisms and epigenetic alterations could cause changes in protein level and/or 
structure to influence the function of key proteins in individual patients. Although 
knowledge on individual variability of the Nrf2 pathway remains sparse, a few recent 
studies provided examples that illustrate potential connections between Nrf2 polymorphisms 
and development of human diseases.
Position cloning of murine susceptibility genes for oxidant-induced acute lung injury 
identified Nrf2 as a candidate susceptibility gene for acute lung injury (Cho et al., 2002b). A 
human single-nucleotide polymorphism (SNP) (−617C/A) was identified in the promoter 
region of human Nrf2 (Marzec et al., 2007). The SNP significantly diminished the promoter 
activity in a reporter assay of the promoter. A nested case-control study showed that patients 
with the −617A polymorphism had a significantly higher risk for developing acute lung 
injury after major trauma compared with wild type (odds ratio of 6.44; 95% confidence 
interval of 1.34–30.8; p = 0.021), implicating Nrf2 in the protection against oxidant-induced 
acute lung injury in humans.
Among Japanese, three SNPs (i.e., −686A/G, −684G/A, and −650C/A) and one triplet repeat 
polymorphism (i.e., CCG repeats between −20 and −6) were found in the regulatory region 
of human Nrf2 (Yamamoto et al., 2004). The frequency of each polymorphism was 
examined in patients with systemic lupus erythematosus or chronic obstructive pulmonary 
disease. This study did not reveal a close connection between the polymorphisms and the 
risk of these two diseases. In a study with 209 Japanese patients with gastric cancer and 198 
patients with no evidence of gastric malignancies, the −686/−684 A/G allele carriers showed 
a significantly reduced risk for gastric carcinogenesis (p = 0.022), especially for the diffuse 
type (p = 0.02), in Helicobacter pylori-negative cases. The inflammation scores in the 
carriers were significantly lower than those in the non-A/G carriers, suggesting that the 
−686/−684 haplotype is associated with the development of gastric inflammation and gastric 
carcinogenesis (Arisawa et al., 2008a). In a separate study with 89 Japanese patients with 
ulcerative colitis and 141 healthy volunteers, the −686*-684 genotype of Nrf2 was suggested 
to be associated with the development of ulcerative colitis (Arisawa et al., 2008b).
Nrf2 polymorphisms interact with smoking status to affect annual decline in forced 
expiratory volume in 1 s (FEV1) (Masuko et al., 2011). The mean annual FEV1 declines in 
people with rs6726395 (NIH dbSNP database) G/G, G/A, or A/A were significantly 
different (Pcorr = 0.016). A significant interaction between rs6726395 genotype and smoking 
status on the FEV1 decline was found (p for interaction = 0.011). The haplotype 
rs2001350T/rs6726395A/rs1962142A/rs2364722A/rs6721961T was associated with lower 
annual decline in FEV1 (p = 0.004). Therefore, Nrf2-dependent responses to exogenous 
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stimuli may affect annual FEV1 decline in the general population, which is modified by 
smoking status, suggesting a gene-environment interaction in accelerated decline of FEV1.
In African Americans, −653G variant allele carriers (rs35652124) had significantly lower 
forearm blood flow and higher forearm vascular resistance under basal conditions as well as 
in response to bradykinin or sodium nitroprusside, compared with wild-type individuals (P < 
0.05). In whites, although no significant associations were observed with the −653A/G 
genotype, −617A variant allele carriers (rs6721961) had significantly higher forearm 
vascular resistance at baseline and in the presence of bradykinin or sodium nitroprusside, 
compared with wild-type individuals (P < 0.05). These findings suggest that polymorphisms 
within the NFE2L2 promoter were associated with impaired forearm vasodilator responses 
in an endothelial-independent manner, supporting a role of Nrf2 in the regulation of vascular 
function in humans (Marczak et al., 2012).
VI. Targeting the Nuclear Factor Erythroid 2-Related Factor 2 Signaling-
Antioxidant Response Element Pathway for Drug Development: Going 
beyond the Promise
The rapid advancement in understanding the biology and signaling mechanism of the Nrf2-
ARE pathway has facilitated the development of ARE inducers as preventive and 
therapeutic agents in several ways. Dissection of the Nrf2-ARE signaling pathway has 
provided target molecules for mechanistic analysis of chemoprotection at molecular levels. 
Because Nrf2 is implicated in an increasing list of disease processes, the spectrum of target 
disease of ARE inducers has expanded beyond cancer to include many chronic diseases and 
toxicity. Development of new ARE inducers with potencies of <1 nM opened new 
possibilities to animal study and clinical trials. The observation that the cytoprotective effect 
of Nrf2 can be hijacked by cancer cells raised concerns about the potential perilous effects 
of Nrf2 activation but, at the same time, brought up the possibility of developing Nrf2 
inhibitors to treat cancers with elevated Nrf2 functions.
A. New and Potent Antioxidant Response Element Inducers
Because the initial validation of phenolic inducers as effective chemopreventive agents, 
many new ARE inducers have been found from a variety of sources, including natural 
products and derivatives, environmental agents, clinical drugs, and endogenous compounds 
(Figs. 1 and 2). Among the inducers, oltipraz (a dithiolethione antiparasitic drug), 
sulforaphane (an isothiocyante), and some Michael reaction acceptors (coumarins, 
curcuminoids, chalcones, cinnamic acid derivatives, flavonoids and related synthetic 
bis(benzylidene)alkanone deviratives, and triterpenoids) have been examined in animal 
studies and some in clinical trials.
A series of triterpenoid analogs of oleanolic acid were synthesized as anticancer agents (Fig. 
6A) (Liby et al., 2007b). The triterpenoids were identified as highly potent inducers of ARE-
dependent genes, and the potency for induction of NQO1 was closely correlated (over 5 
orders of magnitude) with the potency for inhibition of iNOS, a marker and mediator of 
inflammatory response (Dinkova-Kostova et al., 2005). To date, the triterpenoids are found 
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to be among the most potent inducers of ARE-dependent genes. For a comparison, the 
potency for induction of ARE-dependent genes in mouse hepa1c1c7 cells (expressed as 
concentration required for doubling the specific activity of NQO1) is 2 nM for CDDO-Im 
(imidazolide of CDDO), 100 nM for sulforaphane, 10 μM for oltipraz, and 45 mM for BHT 
(Kensler and Wakabayashi, 2010). Triterpenoid inducers have been shown effective in 
protection against toxicity, cancer, and chronic diseases in a range of animal models. 
CDDO-Me (bardoxolone methyl) has successfully completed a phase II clinical trial for the 
treatment of chronic kidney disease associated with type 2 diabetes with a relatively mild 
safety profile (Pergola et al., 2011; Crunkhorn, 2012).
Triterpenoid inducers interact with Keap1 cysteine thiols through Michael acceptor addition 
reaction in which a nucleophilic group, such as a cysteine thiol of Keap1, attacks the α,β-
unsaturated carbonyl structures present in the A and C rings of triterpenoids, producing 
CDDO-Keap1 adducts. The cyano enone moiety in the A ring is more electrophilic than the 
enone group in the C ring (conjugated alkene and ketone) because of an additional cyano 
group (–C≡N). TBE 31 is an acetylenic tricyclic bis(cyano enone), which has a cyano enone 
in both A and C rings (Fig. 6A). The potency of TBE 31 for induction of NQO1 expressed 
in Dm (i.e., the concentration of inducer to cause 50% effect) is 1.1 nM, which is close to 
those of TP-225 (Dm = 0.27 nM, the most potent inducer so far) and CDDO (Dm = 2.5 nM) 
but is 31-fold lower than that of MCE 1 (Dm = 34 nM, a C ring-based, monocyclic cyano 
enone inducer) and is 264-fold less than that of sulforaphane (Dm = 290 nM) (Dinkova-
Kostova et al., 2010). Both cyano enone moieties of TBE 31 react with Keap1 cysteine 
thiols to activate transcription of ARE-dependent genes, but the cyano enone in the C ring 
contributes more to inducer potency than that of the A ring, which is influenced by its spatial 
proximity to an acetylenic group in the C ring. The presence of two cyano enone moieties in 
A and C rings within a rigid three-ring molecule is likely to facilitate binding of the inducer 
to vicinal cysteine thiols of Keap1 to result in an exceptionally high inducer potency (Fig. 
6B). These structure-activity relationships of triterpenoids and derivatives for induction of 
ARE-dependent genes are likely applicable to inhibition of inflammation by the inducers 
because of the close correlation between ARE induction and iNOS inhibition, although the 
molecular events underlying inhibition of iNOS by the inducers is less well defined (Honda 
et al., 2011).
Inhibition of Keap1-Nrf2 binding by peptide inhibitors provides another lead way for 
developing Nrf2 activators. A series of peptide inhibitors were synthesized based on the 
Nrf2 Neh2 domain and the peptide sequences of p62 and prothymosin-α, which are known 
to bind Keap1 DC competitively with Nrf2 Neh2. Among the peptide inhibitors, hybrid 
peptides based on the Nrf2 ETGE motif and the binding sequence of p62 exhibited superior 
binding activities (Hancock et al., 2012). However, modification of the peptides to increase 
stability is needed before the inhibitors can be evaluated in cell-and animal-based models.
B. Cancer Prevention and Therapy
Cruciferous vegetables such as broccoli contain anticarcinogens, such as glucoraphanin, the 
principal glucosinolate in broccoli sprouts. Glucoraphanin can be hydrolyzed by myrosinase 
in the plant or by gut microflora to sulforaphane (Zhang et al., 1992; Fahey et al., 2001). The 
Ma and He Page 26













effectiveness of broccoli sprouts on urinary levels of aflatoxin-DNA adducts and 
phenanthrene tetrols was examined in a randomized clinical trial in He Zuo township, 
Qidong, China, where the incidence of hepatocellular carcinoma is high because of the 
consumption of aflatoxin-contaminated foods (Kensler et al., 2005). An inverse association 
was observed for excretion of dithiocarbamates and aflatoxin-DNA adducts (p =0.002; r 
=0.31) in persons receiving broccoli sprout glucosinolate, although striking interindividual 
differences in bioavailability were noted. In animal studies, sulforaphane induced GSTs and 
NQO1 in wild-type but not Nrf2-deficient mice (Fahey et al., 2002). In an agreement with 
the induction activity, sulforaphane prevented Bp-induced tumor formation in the 
forestomach and inhibited extracellular, intracellular, and antibiotic-resistant strains of H. 
pylori, a risk factor for stomach cancer.
A placebo-controlled, double blind clinical trial of oltipraz was conducted in residents of 
Qidong, China, who have increased risks of liver cancer (Kensler et al., 2000). Oltipraz 
significantly increased excretion of aflatoxin-mercapturic acid, a derivative of the aflatoxin-
glutathione conjugate, in the urine of participants receiving 125 mg of oltipraz by mouth 
daily, whereas administration of 500 mg of oltipraz once a week led to a significant 
reduction in the excretion of the primary oxidative metabolite of aflatoxin B1 (i.e., aflatoxin 
M1). In animal studies, oltipraz induced GST and NQO1 in wild-type mice by 2- and 5-fold, 
respectively, and significantly reduced the multiplicity of Bp-induced gastric neoplasia in 
the mice by 55% but had no effect on enzyme induction and tumor burden in Nrf2-null mice 
(Ramos-Gomez et al., 2001). Oltipraz significantly reduced Bp-DNA adduct formation 
(measured as tetrol) in the forestomach of the wild-type but not Nrf2-null mice (Ramos-
Gomez et al., 2003). Oltipraz reduced the incidence of urinary bladder carcinoma by BBN in 
wild-type mice but had little effect in Nrf2-null mice (Iida et al., 2004). The anti-BBN 
bladder cancer effect of oltipraz was accompanied with significant induction of BBN 
glucuronidation, resulting from induction of UGTs, and reduction of urinary excretion of N-
nitrosobutyl(3-carboxypropyl)amine, a proximate carcinogen of BBN, in wild-type mice, 
indicating reduced metabolic activation of BBN.
Triterpenoids potently inhibit tumorigenesis in animal studies. CDDO-Im inhibited 
aflatoxin-induced tumor formation in rat liver (Yates et al., 2006). CDDO-Im treatment 
caused an 85% reduction in the hepatic focal burden of preneoplastic lesions (i.e., GST-P 
positive foci) at 1 μmol/kg body weight and a >99% reduction at 100 μmol/kg body weight. 
Inhibition of tumorigenesis was accompanied with reduction of aflatoxin-DNA adducts by 
approximately 40 to 90% over the dose range. ARE-dependent genes were induced in an 
Nrf2-dependent manner in mouse liver after treatment with CDDO-Im. CDDO-Im was 100-
fold more potent than oltipraz in this rat antitumorigenesis model. The methyl ester and 
ethyl amide of CDDO (CDDO-Me and CDDO-EA) prevented the development of lung 
cancer induced by vinyl carbamate in A/J mice, markedly reducing the number, size, and 
severity of lung carcinomas (Liby et al., 2007a). TBE-31 is among the most potent ARE 
inducer; oral administration of TBE-31 significantly reduced the formation of aflatoxin-
DNA adducts and decreased the size and number of aflatoxin-induced preneoplastic hepatic 
lesions in rats by >90% (Liby et al., 2008).
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C. Targeting Chronic Disease and Toxicity
On characterizing phenolic antioxidants for gene regulation, the inducers were found to 
exhibit potent anti-inflammatory activities, such as inhibition of the NF-κB signaling 
pathway and production of pro-inflammatory cytokines, including tumor necrosis factor α, 
interleukin 1β, and interleukin 6 in macrophages (Ma and Kinneer, 2002; Ma et al., 2003). 
This observation led to the proposal of chemoprotection for both chronic disease and cancer, 
as opposed to chemoprevention, which is traditionally proposed for cancer prevention. Many 
ARE inducers, including oltipraz, sulforaphane, and lately triterpenoids, have now been 
shown capable of both inducing ARE-dependent genes and inhibiting inflammatory 
response (Dinkova-Kostova et al., 2005; Killeen et al., 2006; Talalay et al., 2007; Liu et al., 
2008b; Honda et al., 2011). Accordingly, ARE inducers have been examined for protection 
against a variety of chronic diseases and toxicity in an Nrf2-dependent manner over the past 
decade.
UV radiation (UVR) is a complete carcinogen and elicits a range of pathological events, 
including DNA damage, generation of ROS, inflammation, and immunosuppression. 
Topical application of sulforaphane-rich extracts of 3-day-old broccoli sprouts up-regulated 
ARE-dependent genes in mouse and human skin, which correlated with protection against 
UVR-induced inflammation and edema in mice and reduction of susceptibility of human 
skin to UVR-induced erythema (Talalay et al., 2007). Sulforaphane also induced ARE-
dependent genes in retinal pigment epithelial cells and protected the cells from UVR (UV 
320–400 nm) photooxidative damage, suggesting a potential of sulforaphane for prevention 
of age- and UVR-related macular degeneration (Gao and Talalay, 2004). Oltipraz protected 
mouse liver from α-naphthylisothiocyanate-induced cholestasis (Tanaka et al., 2009). BHA 
protected animals in a number of toxicity models of oxidative and electrophilic stress, 
including methylazoxymethanol acetate-induced liver necrosis and acetaminophen-induced 
hepatotoxicity (Reddy et al., 1982; Hazelton et al., 1986).
The high potency of the new, synthetic triterpenoids in the induction of ARE-dependent 
genes and inhibition of inflammation has raised a high interest in their potentials for 
prevention and therapy against chronic disease and toxicity, such as atherosclerosis, 
hepatitis/hepatic cirrhosis/hepatotoxicity, asthma/emphysema, inflammatory bowel disease/
Crohn’s disease/ulcerative colitis, diabetes, and neurodegeneration, in addition to cancer 
(Liby et al., 2007b). CDDO-Im protected mouse liver from concanavalin A-induced 
inflammatory liver injury and acetaminophen hepatotoxicity in wild-type but not Nrf2-null 
mice (Osburn et al., 2008; Reisman et al., 2009a). CDDO-Im also reduced high fat diet-
induced increases of body weight, fat mass, and liver lipid accumulation in wild-type but not 
Nrf2-null mice (Shin et al., 2009). CDDO prevented ileitis and down-regulated the 
production of inflammatory cytokines in mice infected with Toxoplasma gondii in a mouse 
model of inflammatory bowel disease (Minns et al., 2004). CDDO-MA is protective against 
the loss of dopaminergic neurons and striatal lesions in mouse models of Parkinson’s and 
Huntington’s diseases (Liby et al., 2007b). Dihydro-CDDO-trifluoroethyl amide, a new 
CDDO derivative, activated Nrf2 to suppress oxidative stress in cardiomyocytes, suggesting 
a potential for cardiac diseases (Ichikawa et al., 2009).
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CDDO-Me has been examined in phase II clinical trials for the treatment of chronic kidney 
disease associated with type 2 diabetes, wherein CDDO-Me was associated with 
improvement in the estimated glomerular filtration rate in patients with the diseases at 24 
weeks and improvement persisted at 52 weeks (Pergola et al., 2011). Moreover, the overall 
safety profile of CDDO-Me during the trial is encouraging, including mild muscle spasms, 
hypomagnesemia, and mild liver and intestinal effects (Pergola et al., 2011).
D. Nuclear Factor Erythroid 2-Related Factor 2 Inhibitors
Some cancer cells persistently up-regulate the Nrf2-ARE pathway through somatic 
mutations and epigenetic changes to take advantage of the protective power of the Nrf2 
pathway for growth and survival. This observation suggests that Nrf2 inhibitors are 
potentially effective for anticancer therapy against certain tumors. However, few specific 
inhibitors of Nrf2 are currently available. High-throughput screening for compounds that 
inhibit Nrf2 is potentially useful for developing Nrf2 inhibitors. By screening natural 
products, brusatol, a plant quassinoid with potent antineoplastic activity, was found to 
inhibit the Nrf2-ARE pathway (IC50 = 40 nM) and enhance the efficacy of chemotherapy by 
cis-platin in vivo and in vitro (Ren et al., 2011). Structure-based and domain-specific 
inhibitors of Nrf2 can be developed by analogy with the development of selective inhibitors 
of the AP1 bZip domain from the three-dimensional structure of the AP1 bZip-DNA 
complex (Aikawa et al., 2008). This latter approach may help differentiate among the CNC 
bZip proteins such that only Nrf2, but not other bZip proteins, are inhibited. Mutant Nrf2 or 
Keap1 may exhibit differential sensitivities to individual inhibitors of Nrf2 from tumor to 
tumor. Thus, Nrf2 inhibitors should be characterized with respect to specific mutations in 
tumors, and inhibitor therapy should target persons with tumors bearing mutations that are 
sensitive to the inhibitor through targeted and individualized cancer therapy.
E. Safety Consideration on Pharmacological Activation of Nuclear Factor Erythroid 2-
Related Factor 2
Many small-molecule inducers of ARE-dependent genes are electrophiles, raising the 
question of whether they cause gene mutation and cancer if used as pharmacological agents. 
On the other hand, it is known that electrophiles differ in their modes of interaction with 
macromolecules, in which “hard” and “soft” parameters determine the rates and reversibility 
of interaction with nucleophiles. The reactivity of chemoprotective agents toward cellular 
nucleophiles is distinct from those of the genotoxic electrophilic carcinogens. Michael 
acceptor inducers, such as those of ARE inducers, preferentially react with protein cysteine 
thiolates, which have low pKa and are “soft” bases, rather than the “hard” nucleophiles that 
are found in nucleic acids and are targets of electrophilic carcinogens. This notion is 
supported by the fact that no evidence for direct genotoxicity of ARE inducers was found so 
far (Kensler and Wakabayashi, 2010). In the clinical trial of CDDO-Me in patients with 
chronic kidney disease and type 2 diabetes, the overall safety profile during the 52-week 
treatment is consistent with mild “off target” side effects (Pergola et al., 2011). However, 
safety evaluation of CDDO-Me in larger patient populations is needed in order to detect rare 
and unanticipated adverse events.
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Another safety concern over chemoprotective agents derives from the findings from genetic 
models of Nrf2 activation, in particular 1) the mouse model of Keap1 knockout that causes 
lethality in the early life of mouse and 2) cancers with mutations of Nrf2 and Keap1 that 
promote tumor growth and drug resistance. In these scenarios, persistent activation of Nrf2 
and elevated expression of ARE-dependent genes were the major molecular phenotypes. A 
direct comparison between pharmacological and genetic activation of the Nrf2 pathway was 
performed by comparing the expression levels and patterns of ARE-dependent genes 
induced by CDDO-Im with those of hepatocyte-specific Keap1-knockout mice (Yates et al., 
2009). The findings showed that the pathways affected by both means were similar, but 
genetic disruption caused much stronger and more persistent activation of Nrf2 than CDDO-
Im; CDDO-Im induced pronounced but transient induction of ARE-dependent genes. 
Genetic activation of Nrf2 also resulted in significant induction of more genes within 
functional families than CDDO-Im. These results reveal that activation of the Nrf2 pathway 
by small-molecule inducers does not replicate the magnitude and duration of genetic 
perturbation. Therefore, an optimal activation of the pathway may be achieved in a 
pharmacological range between the biologically effective dose that minimally activates Nrf2 
and a maximal-tolerated dose beyond which “off target” toxicity is induced to avoid any 
substantial side effects (Kensler and Wakabayashi, 2010).
VII. Conclusion
Induction of ARE-dependent DMEs and cytoprotective proteins has been a useful system for 
analyzing cellular defense against electrophiles and oxidants, which are common “stressor” 
molecules of many chemical and pathological insults. Such studies have provided significant 
new insights into the molecular basis of the stress response, in which the interplay among 
Nrf2, Keap1, and ARE inducers dictates the specificity, efficacy, and plasticity of chemical 
sensing and signaling toward electrophiles and oxidants. The functional importance of the 
Nrf2-ARE pathway was underscored by studies with Nrf2 and Keap1 knockout mouse 
models that exhibit altered sensitivities to a wide range of diseases and toxicity. Analysis of 
the pathway was instrumental for the identification of an increasing list of ARE-dependent 
genes with diverse functions and for the development of new and potent ARE inducers, 
some of which have shown efficacy against cancer, chronic diseases, and toxicity. The effect 
of persistent activation of Nrf2, potentially of more harm than benefit, was unveiled; tumor 
cells were found capable of harnessing the protective power of Nrf2 for their own survival.
A few notable questions remain to be addressed. The chemistry of the cysteine codes of 
Keap1 and Nrf2 and their interaction with specific ARE inducers remain largely unclear. 
Presumably, knowledge of the chemical nature of the cysteine codes and structural 
information of their spatial relationship to Nrf2, Keap1, and Cul3 in the E3 complex would 
be useful in addressing the question. Significant progress has been made in developing 
potent and specific ARE inducers as drug leads, whereas the search for Nrf2 inhibitors is 
just beginning. Future drug development would be facilitated by combining Nrf2 signaling-
based high throughput screening, resolution of the three-dimensional structures of target 
proteins, and elucidation of the chemistry of cysteine thiolelectrophile/oxidant interaction. 
Increasingly important is the evaluation of potential side effects, especially those that are 
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rare and unanticipated, of Nrf2 activators and inhibitors as preventive and therapeutic agents 
in large human populations.
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Representative chemical types of ARE inducers. HQ, hydroquinone; BQ, benzoquinone; 
PDA, phenylenediamine; NCHN, 1-nitrocyclohex-1-ene; PCDT, pyrrolidine-1-
carbodithioate; BAL, 2,3-dimercaptopropanol; HPPB, (2-hydroperoxypropan-2-yl)benzene; 
PAO, phenylarsine oxide; PMC, phenylmercury(II) chloride; TMONTMC, 2,2′-((1E,3E,5E,
7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-
nonaene-1,18-diyl)bis(1,3,3-trimethylcyclohex-1-ene).
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ARE inducers from different sources. PEITC, phenethyl isothiocyanate; 15d-PGJ2, 15-
deoxy-Δ12,14-prostaglandin J2.
Ma and He Page 46














Domain structures of mouse Nrf2, small Mafs, and Keap1. NTR, N-terminal region.
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Models of Nrf2 regulation. Under basal conditions, Nrf2 is rapidly polyubiquitinated 
through the Keap1/Cul3/Rbx1–E3 and degraded by the 26S-proteasomes resulting in a short 
half-life. A small portion of Nrf2 accumulates in the nucleus to mediate basal expression of 
ARE-dependent genes to contribute to maintenance of homeostasis. Under stress conditions 
or in the presence of chemoprotective agents, ARE inducers modify the cysteine codes of 
Keap1 and Nrf2 to inhibit polyubiquitination of Nrf2 resulting in activation of Nrf2 and 
induction of ARE-dependent genes to resist stress. Nrf2 plays a more important role in the 
induction of genes, such as NQO1 and GST, than in their basal expression, because, 
presumably, other signaling pathways support basal expression of ARE-dependent genes in 
addition to Nrf2, which may explain why Nrf2 KO mice have a largely normal phenotype in 
unstressed conditions. In certain pathological scenarios, such as cancer and autophagy 
deficiency, interaction between Nrf2 and Keap1 or between Keap1 and Cul3 is altered 
through mutations, epigenetic changes, accumulation of disruptor proteins, leading to 
inhibition of Nrf2 ubiquitination and persistent hyperactivation of Nrf2, a condition that 
promotes tumor growth, drug resistance, and toxicity.
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Cysteine residues of Nrf2 and Keap1.
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Triterpenoid inducers and Michael reaction with cysteine thiols. A, structures of selected 
triterpenoids and tricyclic and monocyclic cyano enones. Two Michael accepter motifs of 
triterpenoids are shown in boxs with broken lines. B, illustration of Michael adduct 
formation between Keap1 cysteine thiols and TBE 31 at two cyano enone sites.
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